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ABBREVIATIONS 
AKI acute kidney injury 
AMH asymptomatic microscopic haematuria 
ANCA      anti-neutrophil cytoplasmic antibody 
BMI         body mass index 
BP            blood pressure 
C3  complement component 3 
C1q part of the complement system 
CCB   calcium channel blockers 
CI confidence intervall 
CKD        chronic kidney disease  
CKD-EPI  chronic kidney disease-epidemiology 
CS            corticosteroids 
CRP         C-reactive proteiin 
eGFR       estimated glomerular filtration rate 
ESKD      end-stage kidney disease  
GBM glomerular basement membrane 
GFR glomerular filtration rate 
GN glomerulonephritis 
Hb            haemoglobin 
Hct           haematocrit 
HD           haemodialysis 
IF immunofluorescence 
Ig             immunoglobulin 
IgA          immunoglobulin A 
IgG immunoglobulin G 
IgM immunoglobulin M 
IgAN       immunoglobulin A nephropathy 
LGP  isolated non-nephrotic proteinuria 
MAP        mean arterial pressure 
MEST mesangial hypercellularity, endocapillary hypercellularity, 
segmental glomerulosclerosis/adhesion, and 
tubular atrophy/interstitial fibrosis  
mIgA       serum monomeric IgA 
NS           nephrotic syndrome  
Ns  non-significant 
S-Creat    serum creatinine 
SIgA        secretory IgA  
SLE systemic lupus erythematosus 
RASb       renin angiotensin blockers 
RRT         renal replacement therapy 
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1. INTRODUCTION 
Most glomerulopathies, even the more common types, are rare diseases. How-
ever, they are important since they frequently affect young people, often cannot 
be cured, and can lead to chronic kidney disease with associated morbidity and 
cost (Floege, Amann 2016). IgA nephropathy (IgAN) remains the most com-
mon primary glomerulonephritis worldwide (Berger, Hinglais 1968, D’Amico 
1987, Levy, Berger 1988, Glassock 2008). Beside diabetic nephropathy, IgAN 
is another important health-care issue in nephrology as it often affects young 
adults, and the nephropathy keeps a slow but relentless clinical course. The 
clinical progression in IgAN varies, and consequent end-stage kidney disease 
(ESKD) occurs in 15% of patients within 10 years (D’Amico 2000), in 30% to 
40% of patients within 20 to 30 years after the first clinical presentation 
(Rychlik et al. 1999, Lai et al. 2016) and in about 50% (or less) of patients 
within 25 years after the diagnosis according to Glassock’s data (Glassock 
2008). The kidney is a target of injury in IgAN, yet the primary defect 
originates from a systemic aberrant glycosylation of O-linked glycans in the 
hinge region of IgA1, resulting in the increased serum levels of galactose-
deficient IgA1 (Gd-IgA1). As the immunochemical abnormality of IgA is not 
corrected by renal transplantation, not surprisingly IgAN can frequently recur in 
allograft. An effective and specific treatment for IgAN is still lacking (Yu et al. 
2011, Lai et al. 2016). 
Immunoglobulin A nephropathy was first described by Berger and Hinglais 
(Berger, Hinglais 1968). However, slow progress in the understanding of 
disease over the 50 decades urged the development of renal biopsy techniques, 
after that the number of publications grew dramatically, and Berger’s original 
report in IgAN investigation is currently listed as a citation classic by the Insti-
tute for Scientific Information (Emancipator 1998).  
Clinically, Berger described the acute and chronic forms of IgAN. The acute 
form, arisen at the peak of infection, was clinically manifested by haematuria, 
without azotemia, oedema and hypertension. Once in many cases resolved, 
haematuria persisted in a few patients, and the episodes of infection exacerbated 
the disease. The chronic form of IgAN showed the persistent haematuria and 
proteinuria. The disease is pathologically characterized by a focal glomerulo-
nephritis with predominant IgA in glomeruli (Berger, Hinglais 1968, Emanci-
pator 1998). Since then, the so-called Berger’s disease has been found to be a 
common glomerulonephritis all over the world, and, in many countries, it is the 
most frequent renal biopsy finding among glomerulonephritic patients (Ots 
1998, Rifai et al. 2008). 
IgA depositions in glomeruli are not only found in primary glomerulo-
nephritis. Berger (Berger, Hinglais 1968) discovered that IgA depositions in 
glomeruli formed an important part also in a systemic form of IgAN, the so-
called Henoch-Schönlein Purpura, and composed a part of Ig depositions in 
lupus nephritis as well. The secondary IgAN, which is uncommon, is also 
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described. Liver cirrhosis, HIV infection, and celiac disease are all associated 
with a high frequency of glomerular IgA deposition. Also, IgAN has been infre-
quently associated with a variety of many other diseases (Berger et al. 1977, 
Abramowsky et al. 1985, Bene et at. 1988, Katz et al. 1979, Helin et al. 1983, 
da Silva et al. 2015). 
Since many features of the pathogenesis of IgA nephropathy are still 
obscure, specific treatment is not yet available (Tomino 2014, Lai et al. 2016). 
General aim of the study was to focus on the characteristics of primary IgAN 
in the Estonian population. The occurrence, clinical manifestations, histopatho-
logical findings according to the Oxford classification, clinicopathological 
correlations with age-related differences, clinical and morphological risk 
factors, long-term outcome with different antihypertensive drug treatment regi-
mens were investigated. Significance of both clinical and morphological 
prognostic risk factors in IgA nephropathy progression was assessed. 
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2. REVIEW OF LITERATURE 
2.1. IgA Nephropathy 
2.1.1. Definition 
Glomerulonephritis characterized by the predominance of IgA among Ig depo-
sits in glomeruli, in the absence of systemic disease or other nonrenal disease, is 
considered primary, or idiopathic, IgAN (Emancipator 1998). Morphologically, 
the disease is defined by the predominance of diffuse, mainly mesangial, gra-
nular deposition of IgA, identified by immunofluorescence or immunohisto-
chemistry and by a variable degree of glomerular damage by light microscopy 
(Parai, Ghose 1985, Emancipator 1998, Roberts 2014). IgAN has a wide 
spectrum of clinical presentations, varying from isolated hematuria to rapidly 
progressive GN. Its clinical presentation and progression in individual patients 
is variable and its course is generally benign in cases without proteinuria, hyper-
tension or reduced glomerular filtration rate (GFR) (Rifai, Dworkin 2008). 
Mesangial IgA deposition might be present in about 5–15% of healthy indivi-
duals, but only about 1 in 50 people with IgA deposits present with a clinical 
disease (Glassock 2008).  
 
 
2.1.2. Etiology and Pathogenesis 
The single diagnostic feature of IgAN is the finding of IgA immune deposits in 
the glomerular mesangium on renal biopsy. An explanation for this finding, and 
the clinical complications with which it is associated, have been the subject of 
considerable investigation. Despite the advance in the understanding of IgA 
immune system in health and the identification of a number of key changes in 
IgA biology in IgAN, no unifying pathological mechanism has been found to 
explain the development of IgAN (Emancipator 1998, Yu et al. 2011, Boyd et 
al. 2012, Lai et al. 2016).  
Synthesis of IgA and immune system. IgA is the most abundant human 
immunoglobulin, a protein, having the synthetic rate approximately 2.7 mg/kg 
per hour. The majority of IgA is produced in mucosal tissues and secreted as 
secretory IgA (SIgA), with a little entering the circulation. A small amount of 
IgA is produced in the bone marrow by plasma cells and enters circulation, 
most in monomeric form (mIgA). The mucosal and systemic compartments 
are tightly linked and regulated, the so-called “mucosa–bone marrow axis” 
and two compartments function dependent on each other (Suzuki, Tomino 
2007, Yu et al. 2011). IgA is divided into two subclasses, IgA1 and IgA2, 
which differ by the absence of an 18-amino acid sequence in the hinge region 
of IgA2 (Narita, Gejyo 2008, Yu et al. 2011). This difference explains the 
resistance of IgA2 against degradation by bacterial proteases in mucosal 
surface. IgA1 comprises 85% of total serum IgA. IgA produced by plasma 
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cells are mainly of IgA1 subclass, 93% in the spleen, peripheral lymph nodes, 
tonsils, nasal mucosa, 60–80% in bronchial mucosa, exocrine glands, duo-
denal, and gastric mucosa, in contrast to a dominance of IgA2 (64%) in the 
colon (Brandtzaeg, Johansen 2005, Yu et al. 2011). Despite the presence of 
significant amounts of IgA2, IgA1 still predominates in the mucosae derived 
from the embryonic foregut, including airways (Emancipator 1998, Yu et al. 
2011). 
The IgA system is different in human and mice. Murine IgA lacks a hinge 
region with O-glycosylation sites. Serum IgA in mice is exclusive polymeric 
in nature. A homologue of IgA receptor FcαRI is not present in mice. These 
differences have limited the development of animal models for IgAN. The 
ddY mouse is a well-known model of spontaneous IgAN. These mice develop 
glomerulonephritis with IgA deposition in the mesangium (Tomino Y 2010).  
Biological function of circulating IgA and IgA receptors. The biological 
activities and physiological functions of circulating IgA are still poorly 
understood. It seems that circulatory IgA plays an obscure but important role 
in immune regulation. The major role of serum monomeric IgA has a power-
ful anti-inflammatory effect, such as the down-regulation of IgG-mediated 
phagocytosis, chemotaxis, bactericidal activity, and cytokine release (Mon-
teinro 2010, Yu et al. 2011). There are five types of IgA receptors: FcαR, 
Fcα/μ receptor, pIgR, the hepatic asialoglycoprotein receptor (ASGPR), and 
transferrin receptor (CD71). FcαRI (CD89) is expressed on Kupffer cells in 
liver, neutrophils, monocytes, and eosinophils. FcαRI plays an essential anti-
inflammatory role in physiology by the transmission of inhibitory signals 
following the binding of mIgA to FcRγ-associated FcαRI. However, in patho-
logy, FcRγ-associated FcαRI favors the pro-inflammatory role. The polymeric 
IgA complexes result in enhanced IgA binding to FcαRI on blood monocytes, 
which activate monocytes. This also leads to the generation of soluble IgA–
FcαRI complexes due to the cleavage of the FcαRI extracellular domain and 
then the release of IgA–FcαRI complexes into circulation. Soluble IgA–FcαRI 
complexes deposit in tissue such as renal mesangium through binding of IgA1 
to the other receptors such as CD71 and initiate inflammation (Monteinro 
2010, Yu et al. 2011). 
Importance of glomerular mesangium. Together with the mesangial 
matrix, the mesangial cells compose the mesangium which form a stalk of a 
glomerular tuft (Emancipator 1998). The mesangial cells are considered to be 
smooth muscle like cells containing contractile microfilaments (Kreisberg et al. 
1985, Emancipator 1998). The mesangial cells are coupled by gap junctions to 
each other and, in series, to the cells of the extraglomerular mesangium of the 
juxtaglomerular apparatus. They elaborate a lot of vasoactive agents or 
hormones, including prostanoids and platelet activating factor and are thought 
to respond by contraction or relaxation to a number of vasoactive hormones, 
such as angiotensin II and atrial natriuretic peptide, for which they have 
receptors (Kreisberg, Venkatachalam 1986).  
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The mesangial cell is an important target cell in many glomerular immune or 
non-immune diseases and characteristically responds by injury, repair and 
proliferation. In this connection, it has been recognized that the mesangial cells 
do not only respond to a number of growth factors and inflammatory mediators 
but can also produce them in an autocrine fashion (Emancipator 1998). These 
processes are responsible for initiating and sustaining the mesangial cell pro-
liferation following injury (Emancipator 1998). Being not a typical phagocyte, 
the mesangial cells can endocytose colloids, macromolecules, protein aggre-
gates, and immune complexes and in this way clear extraneous material that 
finds its way into the mesangial matrix from the circulation (Emancipator 
1998). 
In glomerular disease, the mesangial cell is thought to play a role in the 
sequestration and disposal of circulating immune complexes. The mesangial 
cells are responsible for the production and degradation of the mesangial matrix 
which is frequently increased in glomerular disease. A minority of mesangial 
cells (~2% of total glomerular cells) are phagocytic (Schreiner, Cotran1982).  
The mesangial matrix fills irregular spaces between the mesangial cells and 
contains a large number of common extracellular matrix proteins, including 
several types of collagens (III, IV, V, and VI) as well as several components of 
microfibrillar proteins, also several glycoproteins (fibronectin is the most 
densely accumulated) and several types of proteoglycans (Couchman et al. 
1994). 
Mechanism of glomerular injury in IgAN. The pathophysiology of IgAN 
remains in part unsolved but it is primarily recognized as a mesangiopathic and 
an immune complex disease. The elevated serum levels of IgA were observed in 
about half of the patients with IgAN (Galla 1995, Yu et al. 2011). Increasing 
evidence supports the fact that the underglycosylated IgA-containing immune-
complexes, including IgG antibodies against the glycans of the hinge region of 
IgA1, are key factors for the mesangial deposition and then trigger inflam-
mation and glomerular injury. The polymeric IgA is produced after aberrant 
mucosal IgA response. The displacement of mucosal B cells to systemic 
lymphoid organs and bone marrow may arise from the abnormal trafficking of 
lymphocytes along the mucosa–bone marrow axis involving the changes of 
chemokines and adhesion molecules (Yu et al. 2011). Then, the formed glome-
rular deposits of immune complexes containing undergalactosylated IgA1 acti-
vate the mesangial cells, leading to the local overproduction of cytokines, 
chemokines and complement. Emerging data indicate that mesangial-derived 
mediators that are released following the mesangial deposition of IgA1 lead to a 
podocyte and tubulointerstitial injury via humoral crosstalk (Lai et al. 2016).  
The links between IgAN and the mucosa have been recognized since the 
1970s. In particular, the observation of visible haematuria induced by respi-
ratory infections in the patients with IgAN and the association of IgAN with the 
diseases in which the mucosa plays a part have been taken as the evidence of a 
mucosa-kidney axis (Floege, Amann 2016).  
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2.1.3. Epidemiology and demographic characteristics 
IgA nephropathy, or Berger’s disease, is recognized as the most widespread 
type of glomerulonephritis worldwide and one of the main causes of chronic 
kidney disease (CKD) (Emancipator 1998, Glassock 2008, Rifai, Dworkin 
2008, Cattran et al. 2009, Roberts et al. 2009). The prevalence rate varies across 
different geographical regions. Typically, it is 30–35% of all primary glome-
rular diseases in Asia, but can be up to 45% (Li et al 2002). In Europe, this is 
about 30–40% (Ots 1998, Simon et al. 2004, Rychlik et al. 2004, Covic et al. 
2006, Carvalho et al. 2006, Beitnaraite et al. 2007, Wirta et al. 2008, Werner et 
al. 2009, Braun et al. 2011). Recently in the USA, IgAN was also reported to be 
the most common primary glomerulopathy in young adult Caucasians (Nair, 
Walker 2006, Wyatt, Julian 2013). Primary IgAN occurs at any age (the range 
is 4 to 80 years), but it is particularly common in younger individuals (Simon et 
al. 2004). The peak incidence of IgAN is between 20 and 40 years of life with a 
gradual decline over the remaining years (Nair, Walker 2006). The overall mean 
age is 38 years. Gender is important in epidemiology. Virtually all studies show 
a male predominance of at least 2:1 (Schena 1990, Galla 1995). Series of Asian 
patients show nearly equal involvement in males and females. IgAN patients 
have been reported from all over the world, and the disease is observed in all 
races (Emancipator 1998, Glassock 2008, Rifai, Dworkin 2008, Cattran et al. 
2009, Roberts et al. 2009). 
 
  
2.1.4. Clinical Expression 
2.1.4.1. Clinical Findings 
In the early stages of the disease, many patients have no obvious symptoms and 
have no complaints (D’Amico 1987). In these patients, IgA nephropathy may be 
suspected only during a routine screening or investigation of another condition. 
However, some patients may present with aggressive disease (Donadio et al. 
2002). Patients with IgAN typically present in one of five ways: isolated micro-
hematuria (Gutiérrez et al. 2012, Chan, Gale 2015), one or recurrent episodes of 
visible haematuria, microscopic haematuria and usually mild proteinuria, and 
rare occurring nephrotic syndrome or acute/or chronic renal failure (Galla 1995, 
Donadio et al. 2002).  
Haematuria. Haematuria can result from bleeding anywhere from the 
glomerulus to urethra, and can be divided into glomerular or non-glomerular 
causes. Non-glomerular causes include malignancy, stones, papillary necrosis 
and metabolic disorders. Older adults (especially smokers) should initially be 
investigated to exclude urothelial or renal malignancy, whereas non-neoplastic 
kidney disease is more likely in those under 40. Microhematuria or macrohema-
turia is the most consistent clinical manifestation of IgAN as the presenting 
symptom or sign in 88% and 43% of all patients, respectively (Cornell 2011). 
Microscopic or non-visible haematuria is defined as two or more red cells per 
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high-power field present in a mid-stream urine sample on more than one occa-
sion, and unrelated to exercise, trauma or menstruation. Prevalence ranges 
between 0.18 and 16.1% depending on the population (Cohen, Brown 2003, 
Chan, Gale 2015). Microscopic haematuria of glomerular origin can occur with 
proteinuria, hypertension or renal dysfunction, which indicate kidney damage.  
Isolated microscopic haematuria refers to haematuria in the absence of protei-
nuria, hypertension or renal dysfunction. For many years, isolated microscopic 
haematuria was regarded as ‘benign’ but, while the short-term risk of kidney 
failure is undoubtedly small, it is now known that the increased risk of developing 
ESKD is significantly higher than that of the general population (Vivante et al. 
2011, Gutiérrez et al. 2012, Chan, Gale 2015). The most common cause of micro-
scopic haematuria of glomerular origin is probably IgA nephropathy; frequencies 
by reporters vary from 70% (Rychlik et al. 2004) to 88% (Cornell 2011). How-
ever, some genetic disorders can also present similarly, including Alport syndro-
me and thin basement membrane nephropathy. 
About 40 to 50% of patients present with one or recurrent episodes of visible 
or macroscopic haematuria, usually following an upper respiratory infection 
(Schena 1990, Galla 1995, Cornell 2011). This has sometimes been called 
“synpharyngitic haematuria”. These episodes can be provoked by bacterial 
tonsillitis, or by other viral upper respiratory infections or less often gastrointes-
tinal and urinary tract infections (Galla 1995); they may occur in individuals 
who have already undergone tonsillectomy. It is presumed, although not proven, 
that the first episode represents the onset of the disease. Patients may complain 
of flank pain during acute episodes, which usually reflects the acute swelling of 
the kidney. Low-grade fever may also be present. Most patients have only a few 
episodes of macrohematuria and episodes usually recur for a few years at most 
(Galla 1995, Donadio, Grande 2002).  
Assessment of kidney function. The key outcome measures for the mana-
gement of GN include the assessment of kidney function, particularly the 
measurement of proteinuria and glomerular filtration rate (GFR). 
 Proteinuria. Proteinuria, which is established in urinalysis, is a frequent 
sign of IgAN, encountered to some degree in nearly 57% of patients (Cornell 
2011). The 24-hour protein excretion remains the reference (‘‘gold stan-
dard’’) method for the quantification of proteinuria in patients with GN. 
According to reports, 52% of patients have <1g/d proteinuria, 33% of 
patients have >1g/d proteinuria and 5% (Galla 1995) to 10% (Emancipator 
1998, Cornell 2011) of patients have proteinuria in the nephrotic range, 
which is an uncommon presentation. If present, proteinuria is usually accom-
panied by haematuria and constitutes the other common initial presentation 
in 30–40% of patients – microscopic haematuria and proteinuria (Galla 
1995). Isolated proteinuria is reported as unusual and rare finding in IgAN 
(Berg et al. 1991). 
 GFR. Glomerular filtration is the process by which the kidneys filter the 
blood, removing excess wastes and fluids. Glomerular filtration rate (GFR) 
is a calculation that determines how well the blood is filtered by the kidneys, 
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which is one way to measure the remaining kidney function. GFR is also 
used to find the stage of chronic kidney disease. Glomerular filtration rate is 
usually calculated using a mathematical formula that compares a person's 
size, age, sex, and race to serum creatinine levels. This number is an 
estimated GFR (eGFR) (KDIGO 2013). A eGFR under 60 mL/min/1.73 m² 
may mean chronic kidney disease, and eGFR under 15 mL/min/1.73 m² 
means kidney failure. eGFR may not be a good measure of kidney health in 
some people, such as the very old or very young, obese people, or the 
persons with amputated limbs. Rarely, IgAN patients develop acute kidney 
injury with or without oliguria. This may be due to crescentic IgA nephro-
pathy, or to heavy glomerular haematuria leading to tubular occlu-
sion and/or damage by red cells (Gutiérrez et al. 2007). Up to 20% of 
patients with IgA nephropathy present with severe azotemia that is a long-
standing disease, either because the patients’ condition did not come to early 
medical attention or because the patients were referred late without an 
established diagnosis (Donadio, Grande 2002).  
Hypertension. As with most forms of glomerulonephritis, hypertension is 
common. It occurs infrequently at the time of initial presentations (5 to 10%), 
but more commonly as the course of the disease lengthens (30 to 40%) or when 
IgAN presents beyond the fourth decade of life (Galla 1995). 
 
 
2.1.4.2. Serological and Immunological Findings 
Serum immunoglobulins and complement. The concentration of total serum 
IgA is elevated in 33 to 50% of adults with IgAN and in a somewhat higher 
percentage in children (D’Amico 1986, Galla 1995). However, other immuno-
globulins (IgG, IgM) and complement levels are not elevated (Kim et al 2012). 
Tests of limited utility. A number of other tests have been proposed for the 
evaluation of possible IgAN presence, but none of them are recommended 
being tests of limited utility (Barrat, Feehally 2016). These tests include 
searching for several circulating autoantibodies or immune complexes. 
 Although circulating autoantibodies including anti-gliadin (Sategna-
Guidetti et al. 1992, Ots et al. 1998) or anti-endothelin (Barrat, Feehally 
2016) antibodies have been reported in IgAN, none appear to be disease 
specific.  
 Circulating IgA-rheumatoid factors and IgA-immune complexes 
have been considered as diagnostic markers but are not diag-
nostically useful, nor can they be reliably correlated with the 
disease activity. 
 Circulating IgA-fibronectin complexes were proposed as a diagnos-
tic test since their presence carried the implication that increased 
reactivity between patient IgA and fibronectin within the glome-
rular mesangium might provide an explanation for the mesangial 
IgA deposition. However, it is now clear that the assays developed 
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for this purpose do not reliably distinguish between IgA complexed 
to fibronectin and free IgA (Cederholm et al.1998). 
 Skin biopsy, looking for IgA deposition in the dermal capillaries, has 
not proven to be sufficiently predictive in IgA nephropathy (Hasbargen, 
Copley 1985). 
 Plasma polymeric IgA1 levels are elevated in 30 to 50 percent of cases, 
but this suggestive finding is not sufficiently specific to establish the 
diagnosis (Hastings et al 2013). 
 The measurement of the proportion of poorly galactosylated IgA1 O-
glycoforms in the serum with or without measurement of poorly 
galactosylated IgA1-specific IgG antibodies has been proposed as a 
clinically useful diagnostic test (Moldoveanu et al. 2007, Suzuki et al. 
2009, Glassock 2009). However, the utility of both assays is unclear 
since neither has been evaluated in patients who do not have IgA 
nephropathy but who present similarly to those with IgA nephropathy, 
such as those with haematuria or renal failure (Roos, Kooten 2007). 
 MicroRNAs (miRNAs) are endogenous small (18 to 24 nucleotides 
long) noncoding single-stranded RNAs that regulate gene expression at 
the posttranscriptional level (Szeto, Li 2014, Trionfini et al. 2015). 
Certain miRNAs, including miR-148b and let-7b, can affect O-galacto-
sylation of IgA1. These two miRNAs were measured in sera from 533 
patients with or without IgA nephropathy to test the diagnostic utility of 
these potential biomarkers (Serino et al. 20016). Both miRNAs were 
elevated in the patients with IgAN, and a diagnostic rule that used them 
in combination had a sensitivity of 64 percent and a specificity of 74 
percent. The positive and negative predictive values for identifying the 
patients with IgAN were 84 and 47 percent, respectively. Thus, these 
miRNAs are of no utility as diagnostic biomarkers (Serino et al. 2016). 
 
 
2.1.4.3. Diagnosis 
At present the suspicion of a diagnosis of IgAN is generally based upon the 
clinical history and laboratory data. The diagnosis can be confirmed only by the 
kidney biopsy with immunofluorescence or immunoperoxidase studies for IgA 
deposits (Galla 1995, Roberts et al. 2009, Emancipator 1998, Barratt, Feehally 
2016).   
 
2.1.5. Histopathology of Renal Biopsy 
2.1.5.1. Light Microscopy (LM) 
The morphological expression on renal injury in IgAN is, like the clinical pre-
sentation, wide ranging and variable. However, much of this variability reflects 
different combinations of glomerular, tubular, vascular, and interstitial lesions 
(Emancipator 1998, Roberts et al. 2009).  
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Glomeruli. All the patterns of immune glomeruli injury are observed in IgAN 
(Emancipator 1998, Roberts et al. 2009). The most common alteration associated 
with IgAN identified by LM is the focal or diffuse expansion of mesangial 
regions, with cells and matrix (Donadio et al. 2002). However, the mesangial cell 
and matrix expansion is not specific for IgAN and can be observed in a number of 
other renal diseases: diabethic nephropathy, focal segmental glomerulosclerosis, 
and a variety of glomerular lesions associated with a systemic disease (Emanci-
pator 1998, Cornell 2011, Roberts et al. 2009). Moreover, a wide variety of 
lesions, such as diffuse endocapillary proliferation, segmental sclerosis, segmental 
necrosis, and cellular crescent formation may be seen in the patients with IgAN 
(Emancipator 1998, Cornell 2011, Roberts et al. 2009).  
 
A –  Light microscopy, PAS stain, x400: the glomerulus shows mesangial 
hypercellularity and expanded mesangial matrix. 
B –  Immunofluorescence shows prominent mesangial IgA deposits, x400. 
Figure 1. Typical morphological alterations in IgA nephropathy 
 
 
Interstitium and tubules. In addition to the glomerular alterations, a variety 
of tubulointerstitial changes may be found in the patients with IgAN. Such 
changes are: interstitial fibrosis, tubular atrophy, interstitial inflammation, and 
red and/or proteinogenous casts within the tubules. These features may be seen 
in progressive renal disease of any course (Emancipator 1998, Donadio, Grande 
2002, Cornell 2011). Nevertheless, the assessment of these features provides an 
important prognostic information for the patients with IgAN (Roberts et al. 
2009). 
Vessels. Vessels do not express any specific features characteristic of IgAN. 
The alteration of vessels are rather associated with hypertension (arteriolohyali-
nosis), secondary or induced by the underlying disease, atherosclerosis in older 
patients (sclerotic arteriopathy), rarely vasculitis (the inflammation of vessel’s 
wall) (Emancipator 1998, Donadio, Grande 2002). 
 
A    B    
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2.1.5.2. Immunofluorescence Microscopy (IF)  
IgAN in the native kidney is defined as a predominant staining with IgA in 
glomeruli by immunofluorsescence or immunoperoxidase. Not all glomeruli 
need to show this positivity. SLE-related nephritis should be excluded. The 
intensity of IgA staining should be more than a trace. The distribution of IgA 
staining should include the presence in the mesangium, with or without 
capillary loop staining, excluding a pure membranous, diffuse, global granular 
GBM staining pattern or a linear GBM staining pattern. IgG and IgM may be 
present, but not in greater intensity than IgA, except that IgM may be prominent 
in sclerotic areas. Complement 3 (C3) may be present. The presence of C1q 
staining in more than trace intensity should bring up the consideration of lupus 
nephritis (Roberts et al. 2009, Bellur et al. 2011). 
 
 
2.1.5.3. Electron Microscopy (EM)  
Amorphous electron-dense deposits in the mesangium and paramesangium 
(100%), subendothelial deposits (11%), subepithelial deposits (6%), sometimes 
intramembranous deposits (2%) are observed. As additional points GMB ab-
normalities often present, also extensive foot processes effacement when protei-
nuria is present are reported. Increased hypercellularity and the increased matrix 
in mesangium are found (Dickersin et al. 2000, Valaitis 2002). 
 
          
2.2. Natural History and Prognosis of IgA Nephropathy 
 2.2.1. Course and Progression  
The idiopathic type of IgAN has only recently attracted the attention of nephro-
logists, since it is becoming evident that it is the most frequent primary glome-
rular disease in the world (D’Amico 1987). Originally it was thought that IgAN 
was a benign disease, but it is now known that approximately one third of 
patients develop a progressive renal disease after a diagnosis which progresses 
to ESKD (Rychlik et al. 1999). Even more, its variable and often long natural 
history makes it difficult to predict an outcome (Bartosik et al. 2001). Two main 
reasons can explain why this disease has long been neglected: (1) its diagnosis 
is based on immunohistological examination which became a routine practice in 
the majority of institutions only at the end of the 60s; (2) the disease is charac-
terized in more than half of patients by almost no clinical symptoms, so that 
biopsy is considered unnecessary by many nephrologists (D’Amico 1987). 
Long-term natural history studies have demonstrated that the rate of pro-
gression has an extremely wide range, from 5 to 25% after 10 years and 25–
50% after 20 years, and a complete remission is reported in 5 to 30% of cases 
(Coppo, D’Amico 2005).  
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2.2.2. Prognostic Indices, Clinical  
The impairment of renal function, sustained hypertension, and marked protei-
nuria at the time of diagnosis are the strongest clinical predictors of an unfavor-
able renal outcome (Radford et al. 1997, Mustonen et al. 2001, Glassock 2008, 
Reich et al. 2007, Le et al. 2011, Wyatt, Julian 2013). Proteinuria at diagnosis 
has been the focus in many studies (Reich et al. 2007, Moriyama et al. 2012, Le 
et al. 2011, and Wyatt, Julian 2013). Particularly, patients with time-averaged 
urinary protein excretion >1.0 g/day have a risk of ESKD that is 46 times the 
risk among patients with values of <0.5 g/day (Wyatt, Julian 2013). Further-
more, the renal outcome is better with a value <0.5 g/day rather then with a 
value 0.5 to 1.0 g/day (Wyatt, Julian 2013). Also, in IgAN, overweight/ obesity, 
present at diagnosis, is associated with an increase in the major risk factors 
(hypertension, proteinuria and severe renal lesions) which translate into a worse 
final outcome (Berthoux et al. 2013). 
 
 
2.2.3. Prognostic Indices, Morphological 
Although the rate of progression is very slow, about 50% (or less) of the 
patients with IgAN progress to ESKD within 25 years (Rychlik et al. 1999, 
Coppo, D’Amico 2005). Beside the clinical prognostic factors of the disease 
progression, pathology studies of IgAN looked for the morphological prognos-
tic indices helping to predict a renal outcome. Some of these indices were 
already known in the 80s-90s, such as glomerular sclerosis, interstitial fibrosis, 
and the involvement of the glomerular capillary wall – all they predict a poor 
outcome (D’Amico 1992, Galla 1995).  
 
The Oxford classification System (2009) – a gold standard for IgAN 
prognostication   
The Oxford classification, which was presented by an international consensus 
group, renewed the interest in the prognostic value of the histologic features of 
the diagnostic renal biopsy (Coppo et al. 2010, Wyatt, Julian 2013). The goal of 
this new system was to identify specific pathological features that more accu-
rately predict the risk of progression of a renal disease in IgAN, thus enabling 
both clinicians and pathologists to improve the prognostication of an individual 
patient. In order to develop this classification, clinical data and renal biopsies 
were obtained from 265 patients who were followed for a median of five years 
(Cattran et al. 2009). The entry criteria for the Oxford study excluded patients 
with and estimated GFR (eGFR) of less than 30 ml per minute per 1.73 m2 of 
body-surface area (excluding the patients with stage 4 or 5 CKD), and the out-
come measure was the progression to ESKD or the decrease in the eGFR of 
more than 50% from the rate at study entry (Cattran et al. 2009, Wyatt, Julian 
2013). Four histologic features showed an independent value for predicting the 
outcome of renal function: mesangial hypercellularity, endocapillary hyper-
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cellularity, segmental glomerulosclerosis, and tubular atrophy/interstitial fibro-
sis – MEST (Roberts et al. 2009, Cattran et al. 2009). The predictive value of 
each of these variables appears to be similar in adults and children (Coppo et al. 
2010). A recent review of 13 Oxford validation studies confirmed the 
independent prognostic value of tubular atrophy and interstitial fibrosis in 10 
studies, mesangial hypercellularity in 4 studies, and segmental sclerosis in 4 
stadies (Roberts 2013, Wyatt, Julian 2013, Karoui et al. 2011, Herzenberg et al. 
2011, Shi et al. 2011, Alamartine et al. 2011, Tanaka et al. 2013, Lee et al. 
2012). Based on these data, the consensus recommendation is that every biopsy 
report of IgAN includes the numerical scores based upon the presence or 
absence of these variables summarised in the MEST score. The pathological 
definitions for grading different renal lesions are summarised in the paper „The 
Oxford classification of IgA nephropathy: pathology definitions, correlations, 
and reproducibility“ (Roberts et al. 2009).   
    
   
2.2.4. Clinicopathological Correlations        
Clinicopathological correlations have been the goal for many researchers, e.g. 
Mustonen 1984, Kawamura 2004, who tried to find independent prognostic 
values for IgAN. The Special IgA Nephropathy Study Group of the Progressive 
Renal Diseases organized by the Ministry of Health, Labor and Welfare in 
Japan conducted a multicenter retrospective case-control study on IgA nephro-
pathy in 2004 to develop an evidence- and lumped-system-based clinico-
pathological classification of IgAN for predicting the long-term risk of pro-
gression to ESKD. The investigators reported that a cellular/fibrocellular 
crescent and glomerular density were found to be the predictors of progression 
in multivariate analyses (Kawamura et al. 2013).    
The recent Oxford classification study of IgA nephropathy published in 2009 
became the gold standard of clinicopathological correlations in the IgAN 
investigation. The correlations between the pathology lesions and clinical 
presentation at renal biopsy in the Oxford study showed that mesangial score, 
segmental glomerulosclerosis, endocapillary hypercellularity, and extracapillary 
proliferation were strongly correlated with proteinuria at the time of biopsy. 
Segmental glomerulosclerosis was correlated with reduced eGFR and higher 
MAP at the time of biopsy. Tubular atrophy/interstitial fibrosis were correlated 
with reduced initial eGFR and higher initial MAP and proteinuria. Arterial 
disease was strongly correlated with initial blood pressure and eGFR but had no 
relation with initial proteinuria (Cattran et al. 2009). 
Correlations between pathology lesions and outcome in the same study also 
have been presented. These correlations have shown that the above mentioned 
pathology features have a value independent of the patients’ clinical parameters 
in predicting the outcome in IgAN. The Oxford study used three widely 
accepted clinical outcomes in the models that assessed the independent 
relevance of these variables (Cattran et al. 2009). 
22 
2.2.5. Remission  
Suzuki and collaborators (Suzuki et al. 2014) proposed the following criteria 
of clinical remission. In the case where the criteria (urinary sediment < 5 red 
blood cells/HPF, the amount of proteinuria < 0,3g/24h) are met for 3 con-
secutive times or more over at least for 6 months, the patients are classified as 
being in the “haematuria remission” or “proteinuria remission,” and both the 
haematuria and the proteinuria remission are defined as the “clinical remis-
sion.” The haematuria or proteinuria remission alone is designated as “partial 
remission.” In addition, the first date on which the remission criteria are met 
is considered as the remission date. 
 
 
2.3. Secondary IgAN 
Most cases of IgA nephropathy are clinically limited to the kidney (Emanci-
pator 1998, Galla 1995, Wyatt, Julian 2013), but IgA nephropathy may be 
associated with other conditions developing into secondary IgAN. An as-
sociation between a glomerular disease and cirrhosis has been known since the 
1950s (Pouria, Feehally 1999). The studies from the 1970s progressed when IF 
came into use and confirmed that mesangial IgA deposition in glomeruli was 
the commonest pattern seen in the patients with liver cirrhosis (Newell 1987, 
Pouria, Feehally 1999).     
Cirrhosis, HIV infection, and celiac disease are all associated with a high 
frequency of glomerular IgA deposition (Pouria, Barratt 2008). However, most 
patients have little or no evidence of glomerular disease. These observations 
indicate that a high circulating load of polyclonal IgA is not in itself adequate to 
promote the nephritis characteristic of IgAN and that other abnormalities of IgA 
and its metabolism are necessary for IgA deposition to translate into mesangial 
activation and glomerular injury. It is also important to note that the reported 
incidence of mesangial IgA deposition in apparently healthy individuals ranges 
from 3 to 16 percent (Barrat , Feehally 2016).  
IgAN has been infrequently associated with a variety of other diseases, in-
cluding dermatitis herpetiformis, seronegative arthritis (particularly ankylosing 
spondylitis), small-cell carcinoma, lymphoma (Hodgkin lymphoma and T-cell 
lymphomas, including mycosis fungoides), disseminated tuberculosis, bronchio-
litis obliterans, and inflammatory bowel disease (Crohn’s disease and ulcerative 
colitis). These are usually clinically evident at the time of biopsy (Galla 1995, 
Pouria, Barratt 2008). 
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2.4. Treatment and the Prevention of  
the Progression of IgA Nephropathy 
2.4.1. General Management of the Patients with  
IgA Nephropathy  
IgA nephropathy is the most common human glomerulonephritis worldwide but 
there is no specific therapy. During 40 years since IgA nephropathy was first 
reported, the cause of this disease has never been clarified. One of the main 
reasons for this was the lack of an appropriate animal model. Since many 
features of the pathogenesis of IgAN are still obscure, specific treatment is not 
yet available. However, efforts by investigators around the world have gra-
dually clarified different aspects of the pathogenesis and treatment of IgA 
nephropathy. Current data implicate overproduction of aberrantly glycosylated 
IgA1 as being pivotal in the induction of renal injury. New therapeutic ap-
proaches will be developed after the pathogenesis of the disease is better 
understood (Tomino 2014, Lai et al. 2016).  
The patients with minor urine abnormalities, normal blood pressure and 
normal GFR usually do well and require only periodic monitoring, such as 
biennial clinic visits. For other patients, the therapeutic options are limited and 
include nonspecific treatment to reduce proteinuria by RAAS blockade and 
non-specific control of inflammation using fish oil and medications such as 
corticosteroids, cytotoxic agents, anti-metabolite, and immunomodulatory drugs 
(Lai et al. 2016).  
The evidence base for the treatment of IgAN is gradually increasing both in 
the number and quality of Publisher trials. There is the consensus that the 
supportive treatment with RAAS blockade and tight BP control should be the 
initial treatments. A part of patients who have persistent proteinuria during 
supportive therapy are still at higher risk for disease progression. There is still 
no consensus if corticosteroids or other immunosuppressive agents soften the 
risk of progression with acceptable toxicity (Boyd et al. 2012). A paucity of 
high-quality clinical trials means that the evaluation of additional therapies, 
particularly immunosuppressive regimens, is difficult and a great deal of 
confusion over the optimal treatment of patients with a high risk for progression 
to chronic kidney disease remains.   
 
 
2.4.2. Treatment and the Prevention of Progression 
Glucocorticoids. Uncertainty exists regarding immunosuppression in patients 
with IgA nephropathy who are at risk of progressive disease (Floege, Eitner 
2011). There is a consensus no longer to give immunosuppression to the 
patients with a GFR below 30 mL/min at presentation unless they already have 
a rapidly progressive glomerulonephritis course. Although glucocorticoids are 
effective for the treatment of the IgAN patients with minor to moderate 
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glomerular injuries, it is necessary to use large doses of the drug for long 
periods. This treatment regimen is associated with severe adverse effects such 
as diabetes, peptic ulcer and aseptic necrosis of the bones. Japanese researches 
reported (Kobayashi et al. 1996) the efficacy of prednisolone (PSL) treatment in 
a 10-year follow-up of the IgAN patients in the early stage (proteinuria of 1–2 
g/day, Ccr of more than 70 mL/min and a histological severity score of more 
than seven) of progressive IgA nephropathy. Tomino and collaborators also 
performed a multicenter trial on PSL in the Japanese patients with IgA nephro-
pathy (Tomino et al. 2004) with good results. However, in a meta-analysis of 
the role of corticosteroids in IgAN, the findings from all studies showed 
reductions in proteinuria, but several researchers detected no benefits for GFR 
(Lv et al. 2009). In particular, the question of whether corticosteroids still bring 
a benefit if added after the optimisation of supportive measures, including 
intense RAS blockade, remains unresolved. The sequence of the first optimising 
supportive measures for 3–6 months before considering corticosteroids in 
patients with persistent proteinuria above 1 g/day and GFR greater than 50 
mL/min has been suggested by the guidelines (KDIGO). 
Angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin-
receptor blockers (ARBs) induce a marked renoprotective effect in patients 
with IgA nephropathy. Combination therapy with an ACE inhibitors and ARBs 
was reported to induce a more pronounced decrease in the progression of 
proteinuria in normotensive patients with IgAN. However, caution should be 
exercised to avoid too large a decrease in BP. RAS blockers are often pre-
scribed for the patients with IgAN and proteinuria. In a meta-analysis of 585 
patients from 11 randomized clinical trials (RCTs) significant renoprotection 
and reduction of proteinuria were achieved with an ACEIs or ARBs versus 
control (Cheng et al. 2009). 
Fish oil. The possible benefit of fish oil containing omega-3 polyunsaturated 
fatty acid in the treatment of IgAN rests on reducing intra-renal inflammation 
by mitigating inflammatory cytokines and eicosanoids. However, the published 
reports failed to show convincing benefits. In the original Mayo Clinic multi-
center study with 106 subjects (Donadio et al. 1994), fewer patients randomly 
assigned for fish oil treatment reached the end-point of at least a 50% rise in 
serum creatinine. In particular, neither this original study nor a subsequent trial 
showed a reduction of proteinuria. Proteinuria is a key therapeutic target 
because it may itself cause renal injury, and its reduction correlates with the 
preservation of renal function. A recent trial of 30 patients suggested that a RAS 
blocker combined with polyunsaturated fatty acids reduced proteinuria more 
than a RAS blocker alone (Ferraro et al. 2009). The KDIGO 2012 Clinical 
Practice Guidelines (Radhakrishnan 2012) suggest an optional use of fish oil in 
the treatment of patients with persistent proteinuria of more than 1 g/day, 
despite 3 to 6 months of optimized supportive care including ACEI or ARBs 
and blood pressure control. Yet, the long-term benefits on preventing ESRD are 
uncertain (Lai et al. 2016). 
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Calcium channel blockers (CCBs). CCBs such as amlodipine and 
nifedipine, which selectively block L-type calcium channels, can dilate afferent 
arterioles but not efferent arterioles in the glomeruli. Therefore, these drugs 
elevate the glomerular pressure, even though they increase the renal blood flow, 
and thereby induce exacerbation of renal dysfunction. Several subtypes of 
calcium channels, such as L, T and N channels, have been identified. Recent 
studies have revealed that inhibitory action on N- and T-type calcium channels 
is useful in the treatment of various renal diseases. CCBs capable of inhibiting 
N- and T-type calcium channels dilate the efferent arterioles. Possible factors 
involved in this effect include the suppression of sympathetic activity mediated 
by the inhibition of N-type calcium channels and the correction of renal hemo-
dynamics mediated by the inhibition of T-type calcium channels (Takenaka at 
al. 2009). Benidipine inhibits not only the L-type, but also the T-type and N-
type calcium channels. Previous clinical studies involving hypertensive CKD 
patients have shown that benidipine has a more potent renoprotective effect 
compared to nifedipine and amlodipine which are known to inhibit L-type 
calcium channels (Hayashi et al. 2007). Clinical and preclinical studies have 
demonstrated that benidipine dilates both afferent and efferent renal arterioles, 
leading to the reduction in the glomerular pressure and the alleviation of 
proteinuria. The long-term antiproteinuric effect of benidipine has not been 
evaluated in detail in hypertensive CKD patients including those with IgA 
nephropathy (Tomino et al. 2011). 
Tonsillectomy with steroid pulse therapy The tonsils are mucosa-as-
sociated lymphoid tissues that come in close contact with extrinsic antigens, 
especially infectious antigens, and are the sites of the initiation of immune 
responses. In recent years, there has been much focus on tonsils. Macroscopic 
haematuria is occasionally observed after acute tonsillitis and/or pharyngitis in 
patients with IgA nephropathy. The clinical effects of tonsillectomy with steroid 
pulse therapy for the treatment of proteinuria and hematuria in patients with 
IgAN have been reported mainly in Japan (Miura et al. 2009). 
Outside Japan, the benefits of tonsillectomy have not been documented until 
2016 when Feehally and others (Feehally et al. 2016) recently showed that in 
the large VALIGA cohort of the European subjects with IgAN, no significant 
correlation was found between tonsillectomy and the decline of renal function. 
 
 
2.5. Experimental Models  
2.5.1. IgAN Experimental Models 
The availability of adequate animal models may speed up the discovery of the 
biomarkers for the disease staging and the individualization of therapy as well 
as the design and testing of novel therapeutic strategies. One of the main 
reasons for the clarification of the cause of IgAN was the lack of an appropriate 
animal model. In 1979, a passive transfer of dinitrophenol conjugated to BSA 
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was reported to cause mesangial IgA deposition, mesangial matrix expansion 
and haematuria in rats (Rifai et al.1979). Murine models include oral xeno-
immunization resulting inglomerular IgA deposition (Emancipator et al.1983); 
spontaneous IgA nephropathy in a non-inbred dd-stock named ddY mice (Imai 
et al.1985). Since then, the findings in the ddY mouse have been extrapolated 
towards the pathogenesis and treatment of patients with IgA nephropathy 
(Tomino et al. 2014). In 1985, Imai (Imai et al. 1985) first reported that the ddY 
(Deutschland, Denken, Yoken) strain of mouse could serve as a spontaneous 
animal model for the human IgA nephropathy. Imported from Germany before 
1920, ddY mice have since then been maintained in Japan. These ddY mice 
exhibit mild proteinuria without haematuria and mesangioproliferative glomeru-
lonephritis with glomerular IgA deposits. These immunopathological findings 
appear when the mice are over 40 weeks of age. Although the incidence of IgA 
nephropathy in ddY mice is highly variable, it appears that the clinicopatho-
logical aberrations besides haematuria in ddY mice resemble those in the IgA 
nephropathy patients (Tomino et al. 2014). In Tomino research division, 
sequential renal biopsies were performed on more than 360 ddY mice (Tomino 
et al. 2014). IgA nephropathy occurred in about 30% of the mice by 20 weeks 
of age (early onset group) and in about 30% of the mice at 40 weeks of age (late 
onset group). IgA nephropathy did not occur in the remaining mice (the 
quiescent group) (Suzuki et al.2005). When an “association study” on onset was 
performed on the early onset and the quiescent groups of mice, multiple disease 
receptor gene loci were observed (Suzuki et al. 2005). Since one of the loci was 
found to be homologous with the gene locus reported for the human familial 
IgA nephropathy, at least some of these mice appear to be subject to the same 
genetic regulation as human IgA nephropathy. Therefore, ddY mice were con-
sidered to be useful as an animal model (Suzuki et al. 2005, Okazaki et al. 
2012). 
Murine models include finally, the advent of transgenic, knockout, and 
knock-in models. However, none of these models allowed the identification of 
the factors that control the transition between the disease onset and progression 
to end-stage renal disease. Thus, good models of IgA nephropathy leading to 
kidney failure that mimic the pathogenesis of the human disease are needed. 
(Ortiz et al. 2015). 
 
 
2.5.2. CKD Experimental Models  
Many longstanding animal models have failed to result in therapeutic advances 
in the clinical setting, such as the kidney ischemia-reperfusion injury and dia-
betic nephropathy models. In this regard, most models for diabetic nephropathy 
are unsatisfactory because they do not evolve into renal failure. Satisfactory 
models for additional nephropathies including IgAN are urgently needed (Ortiz 
et al. 2015).  
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However, CKD models may be used to study the pathogenesis and therapy 
of kidney diseases or to study the systemic consequences of decreased kidney 
function. Subtotal (5/6) nephrectomy (the remnant kidney) has been a mainstay 
of studies of progressive CKD. This non-immunological model is the equivalent 
to the humans having lost a part of the functional mass of the kidney and pro-
gressing despite the removal of the original cause of the kidney injury. Both in 
rats and mice, unilateral nephrectomy and either partial infarction or the ampu-
tation of the poles of the remaining kidney result in the progressive glomerular 
and tubulo-interstitial injury, the loss of remnant nephrons and the development 
of systemic and glomerular hypertension. It is also associated with the progres-
sive intrarenal capillary loss, inflammation and glomerulosclerosis. (Ortiz et al. 
2015). The “remnant kidney” chronic kidney disease (CKD) progression theory 
based on hemodynamic, proteinuric and inflammatory mechanisms consequent 
to nephron loss has not been confirmed in a human disease. Bazzi and 
collaborators aimed to evaluate whether some of these mechanisms are present 
in IgA nephropathy and predict a functional outcome. And finally, they found 
that in IgAN, progressive nephron loss is associated with an increase of 
proteinuric markers of glomerular and tubular damage. Fractional excretion of 
IgG/SG is the best outcome predictor. These data represent the first validation 
in a human disease of some pathophysiological mechanisms of CKD progres-
sion theory (Bazzi et al. 2012). 
Taken together, the remnant kidney experimental model remained a main-
stay of the studies of progressive CKD. 
 
 
2.6 Summary of the literature 
IgA nephropathy (IgAN) remains the most common primary glomerulonephritis 
worldwide (Berger, Hinglais 1968, D’Amico 1987, Levy, Berger 1988, Glas-
sock 2008). Beside diabetic nephropathy, IgAN is another important health-care 
issue in nephrology as it often affects young adults, and the nephropathy keeps 
a slow but relentless clinical course. The clinical progression in IgAN varies, 
and consequent end-stage kidney disease (ESKD) occurs in about 50% (or less) 
of patients within 25 years after the diagnosis according to Glassock’s data 
(Glassock 2008). The kidney is a target of injury in IgAN, yet the primary 
defect originates from a systemic aberrant glycosylation of O-linked glycans in 
the hinge region of IgA1, resulting in the increased serum levels of galactose-
deficient IgA1 (Gd-IgA1). As the immunochemical abnormality of IgA is not 
corrected by renal transplantation, IgAN can frequently recur in allograft.  
At present the suspicion of a diagnosis of IgAN is generally based on the 
clinical history and laboratory data. The diagnosis can be confirmed only by the 
kidney biopsy with immunofluorescence or immunoperoxidase studies for IgA 
deposits (Galla 1995, Roberts et al. 2009, Emancipator 1998, Barratt, Feehally 
2016). The impairment of renal function, sustained hypertension, and marked 
proteinuria at the time of diagnosis are the strongest clinical predictors of an 
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unfavourable renal outcome (Radford et al. 1997, Mustonen et al. 2001, 
Glassock 2008, Reich et al. 2007, Le et al. 2011, Wyatt, Julian 2013). Protei-
nuria at diagnosis has been the focus in many studies (Reich et al. 2007, 
Moriyama et al. 2012, Le et al. 2011, and Wyatt, Julian 2013). Particularly, 
patients with time-averaged urinary protein excretion >1.0 g/day have a risk of 
ESKD that is 46 times the risk among patients with values of <0.5 g/day 
(Wyatt, Julian 2013). Also, in IgAN, overweight/obesity, present at diagnosis, is 
associated with an increase in the major risk factors (hypertension, proteinuria 
and severe renal lesions) which translate into a worse final outcome (Berthoux 
et al. 2013). Beside the clinical prognostic factors of the disease progression, 
pathology studies of IgAN looked for the morphological prognostic indices 
helping to predict a renal outcome. The Oxford classification, which was 
presented by an international consensus group in 2009, is a gold standard for 
IgAN prognostication. Four histologic features showed an independent value 
for predicting the outcome of renal function: mesangial hypercellularity, endo-
capillary hypercellularity, segmental glomerulosclerosis, and tubular atrophy/ 
interstitial fibrosis – MEST (Roberts et al. 2009, Cattran et al. 2009). The 
consensus recommendation is that every biopsy report of IgAN includes the 
numerical scores based on the presence or absence of these variables summa-
rised in the MEST score. Also, the recent Oxford classification study of IgA 
nephropathy published in 2009 became the gold standard of clinicopathological 
correlations in the IgAN investigation. The correlations between the pathology 
lesions and clinical presentation at renal biopsy in the Oxford study showed that 
mesangial score, segmental glomerulosclerosis, endocapillary hypercellularity, 
and extracapillary proliferation were strongly correlated with proteinuria at the 
time of biopsy. Segmental glomerulosclerosis was correlated with reduced 
eGFR and higher MAP at the time of biopsy. Tubular atrophy/intersti-
tial fibrosis were correlated with reduced initial eGFR and higher initial MAP 
and proteinuria.  
An effective and specific treatment for IgAN is still lacking (Yu et al. 2011, 
Lai et al. 2016).  
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3. AIMS OF THE STUDY  
The general aim of the present study was to analyse the single-centre kidney 
biopsy material evaluating the occurrence of IgA nephropathy and assessing its 
clinicomorphological correlations according to the Oxford classification. We 
hypothesized, firstly, that the occurrence of IgA nephropathy has not signifi-
cantly changed in the course of time in comparison with the historically con-
ducted study at the same centre; secondly, that potential gender-related differen-
ces regarding the IgA nephropathy progression exist, and finally, that renopro-
tection has a benefit in the outcome of IgA nephropathy patients. 
   
AIMS OF THE STUDY 
1. To find the occurrence of various glomerulopathies, including IgA nephro-
pathy, in the native kidney biopsy material at the Tartu University Hospital. 
2. To identify the clinical presentation and the morphological patterns of IgAN 
at the time of biopsy according to the Oxford classification.  
3. To assess the clinical and morphological data correlations in IgAN patients 
and to define their gender-related differences. 
4. To assess clinical and morphological prognostic risk factors and their long-
term significance in the IgA nephropathy progression.  
5. To explore a benefit of renoprotection in the outcome of IgA nephropathy 
patients. 
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4. PATIENTS AND METHODS 
4.1. Ethical Considerations 
Paper I. The study is a part of the epidemiology project on chronic kidney 
disease in Estonia (Ethics Committee of the University of Tartu, Minutes nr 
141/30, 19.09.2005 and164/T-0, 22.10.2007). 
Papers II and III. The Research Ethics Committee of the University of Tartu 
has approved this study (Minutes No. 212/T-13, 2012). 
 
 
4.2. Patients 
The patients were selected according to the native kidney biopsy material at the 
Tartu University Hospital. Over the 10-year study (2001–2010), a total of 578 
native kidney biopsies were performed and retrospectively reviewed. 31 cases 
were excluded from the study I because of insufficient or inadequate kidney 
biopsy samples. In total, 547 kidney biopsies of the patients in the study I were 
included (340 men, 238 women; mean age 39.9 ± 17.9 years). Five percent of 
the patients were children where female predominance was noted. The biopsy 
material, for the investigation by the pathology department, was sent from 4 
separate Estonian hospitals (11 different departments). The exact population 
data were obtained from the database of Statistics Estonia for the calculations of 
biopsy rate and incidence of glomerulopathies in the country. In 2010, the 
kidney biopsy material covered the whole of the Estonian population and the 
biopsy rate calculated for that year was 8.1 per 10x5 of population. (Paper I). A 
total of 88 cases of IgAN, which was defined as glomerulonephritis with the 
predominance of IgA among Ig deposits in glomeruli in the absence of systemic 
disease or other nonrenal disease, during 10 years were registered (Papers II, 
III). 15 patients were excluded from the study II because of insufficient renal 
tissue (less than 8 glomeruli) and the cohort of 73 IgAN patients for study II 
was formed. To allow a comparison with the previous reports, we defined the 
children as ≤15, the younger adults as 16–40, the older adults as 41–65 and the 
elderly as >65 years of age in all studies. The patients’ characteristics of 
different studies are shown in Table 1. 
IgAN patients’ cohort of 64 IgAN patients was formed for the FU study 
(59% males, 41% females). Nine patients were lost to follow-up: 3 patients died 
from trauma or other diseases, 1 patient had terminal renal failure at the time of 
diagnosis, and 5 patients did not complete the necessary control programs and 
protocols.  
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Table 1. The patients’ characteristics in different studies (Papers I-III) 
Study Total number  
of cases, 
 n 
Total number 
of study 
cases,  
n 
Total 
excluded 
from the 
study cases, 
n 
Gender 
M/F 
M/F 
ratio 
Age (years), 
range and 
mean age  
I 
 
578 
 
547 
 
31 
 
340/238
 
3:2 
 
4–79 
39.9 ± 17.9 
II–III 
 
88 73 15 45/28 
 
3:2 16–76 
33.7 ± 13.6 
 
4.3. Clinical and Laboratory Findings  
The clinical data (presenting clinical syndromes) for study I were collected from 
the records of the Tartu University Hospital. The baseline clinical data were 
collected within 3 months from the kidney biopsy and at the end of the follow-
up (FU) for studies II–III: weight (kg), height (cm), body mass index (BMI, 
calculated), smoking history, presenting clinical syndrome at the time of biopsy, 
systolic and diastolic blood pressure (mmHg), serum creatinine (μmol/L), serum 
albumin (g/L), serum cholesterol (mmol/L) and serum triglycerides levels 
(mmol/L). Proteinuria was expressed in grams (g) per 24hrs/1.73m2 in children 
and in grams per 24hrs in adults and was ranked at the intervals < 1 g/24hrs, 1–
3.49 g/24hrs and >3.5 g/24hrs; microhematuria was ranked at the intervals of 
<75, 76–150, >150 erythrocytes/µL. eGFR (ml/min/1.73 m²) was calculated 
using the modified MDRD formula for adults and the Schwartz formula for 
children (Schwartz et al. 2009). Patients were defined as overweight/obese 
when their BMI was >25/30. ESKD was defined as eGFR <15 ml/min/1.73m² 
and as the transition to dialysis or transplantation. According to the Oxford 
classification study, 50% reduction of renal function from baseline eGFR was 
defined as an endpoint. The mean rate of renal function decline was expressed 
as a slope of eGFR during the follow-up. The mean arterial pressure (MAP) was 
defined as diastolic pressure plus a third of the pulse pressure (according to the 
Oxford classification quidelines). 
 
Clinical syndromes:  
 Asymptomatic microhematuria was defined as two or more red cells per 
high-power field presented in a mid-stream urine sample on more than one 
occasion, and unrelated to exercise, trauma or menstruation. 
 Macroscopic haematuria was defined as visible haematuria; stones and 
malignancy were excluded. 
 Asymptomatic microhematuria and proteinuria was defined as greater 
than 3 red blood cells per 1 high-power field by microscopic examination 
and as the increase of the excretion of albumin, the range normally detect-
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able by standard dipsticks, which is not accompanied by clinical mani-
festation. 
 Nephrotic Syndrome (NS) was defined as a combination of nephrotic-range 
proteinuria (> 3.5 g/24hrs) with a low serum albumin level and oedema. 
 Acute renal failure was defined as an abrupt loss of kidney function that 
develops within 7 days. 
 Chronic renal failure was defined as abnormalities of kidney function, 
present for more than 3 months, with implications for health and decreased 
GFR below 60 ml/min/1.73 m2 according to KDIGO and this corresponds 
with the eGFR categories G3a-G5 (KDIGO 2013).   
 
 
4.4. Renal Biopsy 
4.4.1. Kidney Biopsy Procedure 
All renal biopsies were performed percutaneously under ultrasound guidance. A 
14- or 16-gauge automated biopsy needle was used for the procedure. Two 
kidney samples were taken per case: 1 sample for light and 1 sample for 
immunofluorescence microscopy and in selected cases a sample of fresh kidney 
tissue was divided also for electron microscopy. Kidney biopsy complications 
are extremely low and no serious complications were seen in our studied 
patients’ cohort. 
Indications for kidney biopsy: isolated microhematuria, isolated non-
nephrotic proteinuria, nephrotic syndrome, acute nephritic syndrome, unex-
plained acute renal failure. 
 
 
4.4.2. Kidney Biopsy Material 
The routine evaluation of a percutaneous renal biopsy involves the examination 
of the tissue under light and immunofluorescence microscopy (or immuno-
peroxidase in some laboratories (Mölne et al. 2005)). Each component of the 
evaluation can provide important diagnostic information (Whittier et al. 2016).  
Light microscopy (LM). One sample of renal tissue was fixed in 10% 
buffered formalin for light microscopy and after the fixation it was embedded 
into parafin, using routine procedures. The kidney tissue sections were cut at 3 
µm thickness and stained with hematoxylin-eosin, periodic acid Schiff (PAS), 
silver methamine and for elastic fibers (Verhoeff elastic stain). The kidney 
tissue samples were examined, using a Zeiss microscope (Axioskop 40). 
Immunofluorescence microscopy (IF). Another sample of renal tissue was 
snap-frozen or for selected cases it was divided into 2 pieces: one piece for IF 
microscopy with subsequent snap-frozing and one piece for electron micro-
scopic examination. For IF, tissue samples were snap-frozen with isopentane in 
liquid nitrogen and were subsequently cut  by cryostat at 4 µm thickness. IF was 
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based on the use of antisera conjugated with fluorescein directed against human 
antigens such as IgA, IgG, IgM, complement fractions (C3, C1q), and kappa 
and lambda light chains of immunoglobulins (DAKO products). The kidney 
tissue samples were examined, using a Zeiss microscope (Axioskop 40) equip-
ped with the epi-fluorescence illuminator (HBO 100).  
 
 
4.4.3. Microscopic Examination  
Light microscopy (LM). Each biopsy was evaluated according to the clinical 
data of the case and sorted according to the classification of kidney and glo-
merular diseases. Kidney diseases were divided into four categories: (i) primary 
glomerulopathies; (ii) secondary glomerulopathies; (iii) tubulointerstitial 
diseases; and (iv) other conditions. A diagnosis of primary glomerulopathy was 
considered if at the time of biopsy there was no evidence of multisystemic 
disease. Primary glomerulopathies were divided into nine groups: mesangio-
proliferative glomerulonephritis (MesGN), some other than IgA nephropathy or 
lupus nephritis; immunoglobulin A nephropathy (IgAN); membranoprolifera-
tive glomerulonephritis (MPGN); focal and segmental glomerulosclerosis 
(FSGS); minimal change disease (MCD); crescentic/necrotic glomerulo-
nephritis (CGN) without the criteria of systemic disease; membranous glome-
rulonephritis (MGN); diffuse endocapillary proliferative glomerulonephritis 
(DEPGN); and sclerosing glomerulonephritis (SGN). Secondary glomeru-
lopathies were classified according to their association with systemic diseases, 
such as systemic lupus erythematosus, amyloidosis, diabetes mellitus, vascu-
litis, glomerulonephritis associated with infectious diseases (endocarditis) and 
hereditary disorders. (Paper I). Each biopsy, selected for studies II and III, was 
scored by two independent pathologists according to the Oxford Classification. 
A simplified score sheet of the Oxford classification of IgA nephropathy study 
was used (Roberts et al. 2009): total number of glomeruli, mesangial hyper-
cellularity, M0/M1 (< or equivalent to 50% />50% of glomeruli showing >4 
mesangial cells in one area); endocapillary proliferation, E0/E1 (present/ 
absent), segmental glomerulosclerosis/adhesion, S0/ S1 (present/ absent); 
glomerular membrane duplication, necrosis, cellular/fibrocellular crescent were 
categorized as present or absent; tubular atrophy/interstitial fibrosis, according 
to the Oxford classification, tubular atrophy/interstitial fibrosis is measured as 
percentage of cortical area involved by the tubular atrophy or interstitial 
fibrosis, whichever is greater. T0/T1/T2 was categorized as absent/ mild (0%–
25%), moderate (26%–50%) or severe (>50%). Arteriosclerosis (the worst 
arterial vessel was scored) A0/A1/A2 was categorized as absent, < than media 
of arterial vessel and > than media of arterial vessel; arteriolar hyalinosis was 
categorized as absent or present. A0–A2 and arteriolar hyalinosis are not parts 
of the Oxford classification and the items were included in investigation as an 
important morphological features associated with hypertension. Interstitial 
fibrosis and tubular atrophy were taken as one item.  
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Immunofluorescence microscopy (IF). The IF findings were evaluated ac-
cording to guidelines of the Oxford Classification. IgAN in the native kidney is 
defined as dominant or co-dominant staining with IgA in glomeruli by immuno-
fluorescence. Not all glomeruli show this positivity. SLE-nephritis should be 
excluded. The intensity of IgA staining should be more than a trace. The 
distribution of IgA staining should include the presence of granular deposits in 
the mesangium, with or without capillary loop staining, a pure membranous, 
diffuse, global granular GBM staining pattern or a linear GBM staining pattern 
should be excluded. IgG and IgM in minority cases could present, but not in 
greater intensity than IgA; IgM might be prominent in sclerotic areas. C3 could 
be present.  
 
 
4.5. Treatment of IgAN Patients (Papers II, III) 
A drug treatment was prescribed to the patients who had lower eGFR, higher 
proteinuria and more severe histological lesions, while the patients with 
minimal clinical symptoms and the ones with near-normal kidney function 
remained without drug treatment. The treatment information included anti-
hypertensive, immunosuppressive, fish oil and statins medications as well as 
tonsillectomy. Therapy with corticosteroids was not consistent and it has not 
been analysed separately in the current study. The data of the antihypertensive 
drug treatment were detailed, showing the number of medications and the 
classes of antihypertensives: the treatment with renin-angiotensin system 
blockers (RASb): angiotensin converting enzyme inhibitors or angiotensin 
receptor blockers and the treatment with calcium channel blockers (CCB). 
45.8% of the patients did not receive any antihypertensive and immunosuppres-
sive drug treatment.  Thus, the patients were divided into two main study groups 
according to their drug-treatment: drug-treated and untreated patients’ groups. 
Two subgroups among the patients receiving two different antihypertensive 
drugs were formed and statistically analysed: RASb- and CCB-receiving 
patients. Also, patients’ subgroups with and without the presence of clinical 
and/or morphological risk factors were used for statistical analysis.  
 
 
4.6. Clinicomorphological Correlations  
Various correlations between the clinical and pathological variables were 
examined: between MAP, proteinuria, eGFR and the parts of MEST, and 
arteriosclerosis as well; between different levels of proteinuria and eGFR; 
between clinical and morphological risk factors, different treatmen regimens 
and eGFR(FU) (Papers II, III).  
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4.7. Follow-up Study 
The duration of follow-up was the period from the histological diagnosis to the 
last check.  
Most patients of the present study are continuously under the control at the 
departments of nephrology at the Tartu University Hospital or the hospitals of 
Tallinn. The clinical data were collected by the nephrologists at the end of the 
follow-up using a standard form of follow-up dataset. The mean follow-up of 
the cohort (64 patients) was 4.1 years (1–12 years) (Papers II–III).   
 
 
4.8. Statistical Analysis 
All the data were collected in a standard Excel spreadsheet and stored in a stan-
dard Excel database. The statistical analyses was used the Statistica 12.0 pro-
gramme. Descriptive statistics was used to characterize the cohort. The qualita-
tive data were presented as absolute and relative (percentage) frequencies. The 
quantitative data were expressed as the standard deviation intervals (means ± 
SD). A P-value <0.05 was considered to be statistically significant in all ana-
lyses (Papers I, II, III). 
The means of the groups were compared using the Student’s T-test. The 
annual incidence was defined as the number of new cases per year in relation to 
the total population, and expressed per 10x5 of population (Paper I).  
The Spearman Rank Order Correlations were used to assess the bivariate 
relationships. The rate of the renal function decline, expressed as the slope of 
eGFR at the end of the follow-up as a clinical outcome, was analysed (Paper II). 
The medians were compared using the Mann–Whitney U test. The conti-
nuous variables were compared using the Student’s t-test for independent 
samples after verifying the normality of distribution using the Kolmogorov-
Smirnov test or by the analysis of variance (ANOVA) when more patients’ 
groups were compared. The differences of eGFR decrease between the study 
groups were assessed, using the Wilcoxon rank sum test for continuous 
variables. The univariate and multivariate logistic regressions were used to 
examine the correlations between independent and dependent variables. The 
independent variables included: age, gender, BMI, MAP, eGFR, proteinuria, 
smoking history. Spearman Rank Order Correlations were used to assess the 
bivariate relationships between clinical variables and morphological scores 
(Paper III). 
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5. RESULTS  
5.1. Occurrence of Glomerulopathies in Estonia (Paper I) 
Primary glomerulopathies (248 cases) comprised the main part (45.4%) of all 
informative kidney biopsies (total number 547) and IgAN formed the main part of 
them (88 cases, 35.5%). The information about the distribution of glomerular and 
tubulointerstitial diseases is summarized in Table 2. Among primary glomerulo-
pathies, inflammatory damage of glomeruli dominated (63.4%). MesGN was the 
most common type of glomerular damage (41.2%) and IgAN formed the main 
part of it (n = 88, 35.5%), followed by DEPGN (n = 28, 11.3%) and CGN (n = 8, 
3.2%), comprised of “pauci-immune” (ANCA-positive) glomerulonephritis (n = 2), 
pauci-immune (ANCA-negative) glomerulonephritis (n = 1), anti-glomerular 
basement membraane nephritis (n = 2) and non-classified CGN cases (n = 3). 
MPGN was a rare type of glomerular damage in Estonia (7.7%). Noninflammatory 
diseases of glomeruli (MCD, MGN and FSGS) comprised 34.6% of all primary 
glomerulopathy cases (50 males, 36 females), and 0.9% of cases formed SGN. 
FSGS was the most frequent disease (n = 40, 16.1%, mean age 49.7 ± 16.7 years), 
followed by MCD (n = 35, 14.1%, mean age 31.4 ± 18.8 years) and membranous 
nephropathy (n = 11, 4.4%, mean age 42.5 ± 11.8 years). Secondary glomeru-
lopathies in Estonia composed 22.3% (n = 122) of all informative biopsies.  
 
Table 2. Distribution of glomerular and tubulointerstitial diseases  
 
Group of diseases Number of patients, n Percentage, % 
Primary glomerulopathies 
     Mesangioproliferative GN 
     IgA nephropathy 
     Membranoproliferative GN 
     Focal and segmental glomerulosclerosis 
     Minimal change disease 
     Crescentic/necrotic GN 
     Membranous GN 
     Diffuse endocapillary proliferative GN 
     Sclerosing GN 
248   
14 
88 
19 
40 
35 
8 
11 
28 
5 
45.4 
2.6 
16.1 
3.5 
7.3 
6.4 
1.5 
2.0 
5.1 
0.9 
Secondary glomerulonephritis 
     Lupus nephritis 
     Henoch-Schönlein purpura 
     Systemic vasculitis 
     Granulomatosis with polyangiitis 
     GN associated with infectious diseases  
     Renal amyloidosis 
     Diabetic glomerulosclerosis 
     Alport syndrome 
     Other hereditary disorders 
122 
41 
3 
9 
9 
2 
26 
8 
2 
22 
22.3 
7.5 
0.5 
1.6 
1.6 
0.4 
4.8 
1.5 
0.4 
4.0 
Tubulointerstitial diseases 45 8.2 
Other conditions 132 24.1 
Total  547 100.0 
 
GN – glomerulonephritis  
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Gender and age-related differencies of the cohort are shown in the original 
article (Paper I, Tables 2 and 3).   
 
  
5.2. IgAN Study in the Estonian Cohort (Papers II, III)  
5.2.1. Patients 
Between January 2001 and December 2010, a total of 88 patients were diag-
nosed with primary IgAN by renal biopsy. A total of 73 biopsy-proven IgAN 
cases were selected and analysed in the IgAN study: 56 male and 32 female 
patients. The patients’ mean age at the presentation was 33.7 years (16–76 
years): 32.0 for males and 36.4 for females. This glomerulopathy was absent in 
the children’s group (≤15 years) and only two cases (0.8%) of IgA nephropathy 
were registered in the elderly group. The mean age of the patients and gender 
distribution in the cohort is shown in the original article (Paper II, Table 1). 
 
 
5.2.2. Clinical and Laboratory Findings  
The clinical findings and laboratory data are presented in the original article II 
(Table 1).  
The tabel shows the data of the whole cohort and separately the data of male 
and female patients. Te average of time between the onset and the first clinical 
presentation was 2.6 years (range 0.1–21.2 years). In general, the male patients 
at the time of diagnosis had relatively higher eGFR and nobody of male patients 
had immunosupression because of the proteinuria of secondary diseases.  
For the whole cohort, asymptomatic microhematuria and asymptomatic 
microhematuria with proteinuria were the main presenting clinical syndromes, 
comprising 48% and 39% of all cases, respectively. Nephrotic syndrome and 
macroscopic haematuria, which were associated with acute respiratory in-
fection, were rare at presentation (7% and 4%, respectively). There was only 
one patient with acute renal failure and chronic renal failure (eGFR˂60 ml/min/ 
1.73m²) in each group. 
The MAP at the time of biopsy was 94.5±16.7 mmHg and 7% of the patients 
were hypertensive and/or were having an antihypertensive treatment. 
The mean proteinuria at the time of biopsy was similar in both male and 
female patients, 0.95 g/24hrs and 0.86 g/24hrs, respectively; whereas 81% of 
the patients had mild proteinuria <1 g/24hrs. 
The mean eGFR for all cases was 94.9±30.7 ml/min/1.73m², which was 
100.5±32.7 ml/min/1.73m² and 85.8±25.3 ml/min/1.73m² for the male and 
female groups, respectively. To assess the CKD staging the eGFR data were 
used. The distribution of patients to the CKD G1, G2 and G3 stages at pre-
sentation was 55%, 34% and 10%, respectively (men 66%, 23%, 10% and 
women 37%, 52%, 11%), while 1 patient in the male group was within the G5 
stage, and no cases within the G4 stage were registered. The distribution of 
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patients to the CKD G1, G2, G3 and G4 at the end of follow-up in whole cohort 
was 52%, 29%, 16% and 3%.  
Other clinical data, such as BMI, smoking and tonsillectomy, showed little 
differences in presentation between the males and females: the mean BMI was 
higher than normal in both genders and the overweight/obese patients in the 
male and female groups composed 58% and 65%, respectively.  
 
 
5.2.3. Pathomorphological Peculiarities  
5.2.3.1. Light Microscopy (LM) 
The frequency of pathological findings in 73 kidney biopsies is shown in Figure 
2. 
All cases. The typical finding in glomeruli was the expanding of mesangial 
area and the mesangial cell proliferation (73% of cases). These changes were 
mostly global and diffuse and varied in severity from mild to severe. Segmental 
glomerulosclerosis/adhesion was found in 52% of kidney biopsies. Endocapil-
lary cellularity was registered in 32% of specimens. Crescents were found only 
in a few cases. Tubular atrophy/interstitial fibrosis were found in 10% of kidney 
biopsies; however, arteriosclerotic lesions were registered in 35% of all cases. 
 
 
 
Figure 2. The frequency of pathological findings in 73 kidney biopsies 
 
 
All cases 
     
Mesangial                        Endocapillary            Segmental           Tubular atrophy/        Arteriosclerosis 
hypercellularity              hypercellularity            glomerulosclerosis          interstitial fibrosis        (A0/A1/A2) 
(M0/M1)              (E0/E1)             (S0/S1)           (T0/T1/T2) 
 
Male/Female 
     
Mesangial                             Endocapillary           Segmental        Tubular atrophy/                Arteriosclerosis 
hypercellularity                  hypercellularity          glomerulosclerosis       interstitial fibrosis                (A0/A1/A2) 
(M0/M1)                  (E0/E1)            (S0/S1)                 (T0/T1/T2) 
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5.2.3.2. Immunofluorescence Microscopy (IF)  
The IF findings were evaluated according to guidelines of the Oxford Classi-
fication. IgAN in the native kidney was defined as a dominant or codominant 
staining with IgA in glomeruli by immunofluorescence. Not all glomeruli 
showed this positivity. SLE-nephritis was excluded. The intensity of IgA 
staining was more than a trace (moderate (++) or marked (+++/++++)). The 
distribution of IgA staining included the presence of granular deposits in the 
mesangium, with or without capillary loop staining, a pure membranous, 
diffuse, global granular GBM staining pattern or a linear GBM staining pattern 
was excluded. IgM in minority cases was present, but not in greater intensity 
than IgA, and IgM was prominent in sclerotic areas. C3 was present in one third 
of cases. 
  
5.2.3.3. Gender-related Differences 
The gender related differences of pathomorphological findings in 73 kidney 
biopsies are shown in Figure 2. There were not significant differences in the 
glomerular lesions of the male and female groups. The differences appeared in 
tubular atrophy/interstitial fibrosis and arteriosclerosis categories with the male 
prevalence more than twice in both of them (male-female: 13%-4% and 40%-
18%, respectively).  
 
5.2.4. Follow-up Study (FU)   
5.2.4.1. Patients’ Clinical Characteristics at the End of the FU 
Nine patients were lost to the follow-up. For the rest of 64 patients (59% male 
and 41% female), the mean follow-up was 4.1 years. The initial and FU clinical 
data are presented in the original article II, Table 1. The final comparison of the 
initial and the FU data were performed only in the cases where both periods 
were available for analysis (64 patients in total). 
A drug treatment was prescribed for 58% of the patients. The patients in the 
drug-treated group were significantly older (37.5 vs 28.8, p = 0.04), more likely 
to be overweight (27.5 vs 25.2, p = 0.02), with higher serum creatinine level 
(106.1 vs 77.2, p = 0.02) and had lower eGFR than the patients in the untreated 
patients’ group (76.5 vs 98.8, p = 0.01, respectively) (Paper III, Table 1). Table 
2 in Paper III shows clinical picture and drugs prescription to the patients 
according to the clinical syndrome. RASb were prescribed to the patients 
having better kidney function and lower blood pressure. The lowest kidney 
function was noticed in the patients receiving CCBs (Paper III, Table 3). 
At the end of the FU the presenting clinical syndromes in all studied patients 
were similar to the initial clinical presentation (Paper III, Table 2). Macro-
hematuria (11.1%), microhematuria (59.3%) and asymptomatic microhematuria 
with proteinuria (29.6%) were the leading syndromes among untreated patients 
whereas among drug-treated patients no macrohematuria was presented and less 
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microhematuria was registered (34.2%) but more microhematuria with 
proteinuria (50.0%) was found.  
 
 
5.2.4.2. Clinicomorphological Correlations  
The correlations between renal pathology and clinical findings at the time 
of biopsy  
The frequency of the MEST findings was similar in males and females, except 
arteriosclerosis that was more frequent in the male patients (P=0.004). No 
correlation between the parts of the MEST score or arteriolosclerosis as well as 
the levels of MAP in the whole cohort and in both genders was found (Paper II, 
Table 2). However, M1, E1, S1, T1 and A2 were correlated with the levels of 
eGFR and proteinuria. The pathology scoring of the same categories revealed 
the differences in males and females as follows: a statistically significant 
correlation in males was observed between the parts of the MEST score and the 
eGFR, arteriosclerosis and proteinuria as well, except the E score, which didn’t 
reveal significant correlation with proteinuria. In females, no significant 
statistical correlation between the parts of the MEST score and the eGFR was 
found, except the correlation between proteinuria and E, and S. The M did not 
reveal a correlation with eGFR; the arteriosclerosis score correlation with 
proteinuria in females was also statistically insignificant. 
The lowest MEST score was present in the patients’ group having macro-
scopic haematuria. Those patients did not receive treatment. The IgAN patients 
with nephrotic syndrome had the highest MEST score, the prominent clinical 
symptoms and, therefore, all of them received the continuous treatment with 
antihypertensives and temporary treatment with corticosteroids. A higher MEST 
score was also found in patients with asymptomatic microhematuria and 
proteinuria whereas two thirds (71%) of those patients received the continuous 
treatment with antihypertensives (Paper III, Table 2). 
 
Correlations between a clinical presentation and an outcome 
The decline of eGFR in males was faster than in females within a shorter 
follow-up time (Figure 3). The mean rate of renal function decline in the cohort 
was -2.6 ml/min/1.73 m² per year, P<0.05 (-3.4 ml/min/1.73 m² per year in 
males, P<0.05, and -0.7 ml/min/1.73 m² per year in females). The end point was 
reached in 3% of the cases (CKD G4 in two males and in one female) and no 
ESKD cases were registered (Paper II).  
After analysing the patients in two study groups (drug-treated and untreated), 
many statistically significant correlations disappeared in the clinicopathological 
correlation analysis of the drug-treated patients’ group and only a few corre-
lations remained: M correlation between U-Prot (FU); E correlation with U-Prot 
(FU); S correlation with eGFR (FU) and U-Prot as well as with U-Prot (FU);  
T correlation with S-Creat and eGFR as well as with eGFR(FU). Thus, M1,  
E1, S1, T1 and A2 scores were correlated with the levels of MAP, eGFR  
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Figure 3. IgA nephropathy male and female patients’ outcome showing eGFR decline 
during the follow-up. 
 
 
In the untreated patients’ group, only one statistically significant correlation 
between the pathomorphological and clinical risk factors was found: between 
arteriosclerosis and microhematuria (rs = -0.4, p = 0.04). 
 
 
5.2.4.3. IgAN Progression Risk Factors  
The decline of mean eGFR was found in all study groups. (Figure 4, A). The 
changes of eGFR in IgAN patients were found as follows: eGFR decline was 
noticed in 54.8% of patients, in 12.3% of the patients eGFR remained at the 
same level and in 30.2% of the patients it slightly rose. By ANOVA, the decline 
of eGFR was noticed generally in all patients’ subgroups notwithstanding which 
treatment they received or what kind of risk factors, clinical or morphological, 
they had. (Figure 4, B). The trend of eGFR decline was found among the 
subgroups of patients having clinical, morphological or both risk factors which 
statistically was insignificant. Using Mann–Whitney U comparison tests we 
analysed the IgAN treatment subgroups. The following statistically significant 
correlations in IgAN cohort were found: in patients with lower kidney function 
(eGFR <60 ml/min/1.73 m²), higher MAP (p< 0.01) and proteinuria irrespecti-
vely of the fact whether patients received (p< 0.01) or did not receive RASb (p< 
0.01).  
 
 
 
and proteinuria. A higher level of arteriosclerosis and the MEST parts was 
noticed in those patients whose proteinuria was higher and eGFR was lower at 
the end of the follow-up.  
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A – eGFR decline in the IgAN patients’ subgroup according to treatment regimens: un-
treated (N = 27), all drug-treated (N = 38) and RASb- (N = 31) and CCB-treated (N=6). 
B – eGFR decline in the IgAN patients’ subgroups according to clinical and patho-
morphological IgAN progression risk factors: without risk factors (N = 17), with 
clinical risk factors (N = 45), with histological risk factors (N = 38), with clinical and 
histological risk factors (N = 27). 
C – eGFR in the IgAN patients’ subgroups according to risk factors and the presence of 
treatment.  
eGFR – estimated Glomerular Filtration Rate, KBx – kidney biopsy, FU – follow-up 
 
Figure 4. eGFR decline according to treatment regimens and IgAN progression risk factors 
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The dispersion analysis showed that BP affected significantly the dispersal of 
eGFR (p < 0.01), especially when we estimated BP concurrence with smoking 
(p = 0.01). After the FU eGFR was lower in both study groups and more signifi-
cantly among the patients with clinical and morphological risk factors 
(ANOVA). The biggest significant eGFR decline by the Wilcoxon rank sum 
test was found among the patients who had risk factors and received treatment. 
The result was confirmed by a post hoc analysis and did depend on the presence 
of treatment. In the investigation of subgroup receiving RASb we found that the 
decrease of eGFR did depend on the presence of clinical and morphological risk 
factors. Finally, we assessed the study subgroups separately according only to 
major clinical risk factors (overweight/obesity, hypertension, smoking and 
proteinuria), and the following results were found: in patients with major 
clinical risk factors and without drug treatment the decline of eGFR was 13% 
from initial but in those who had major clinical risk factors and received RASb 
it was 10.5%. (Figure 4, C). However, we did not find statistically significant 
reliability for these differences. Thus, there was not progression of IgA 
nephropathy in the patients groups without risk factors and without treatment, 
and without risk factors and with RASb treatment. 
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6. GENERAL DISCUSSION  
6.1. Occurrence of Glomerulopathies  
6.1.1. Indications for Renal Biopsy 
The occurrence of glomerulopathies in biopsy material depends on the indica-
tions for a biopsy, which only indirectly reflect the spectrum of chronic kidney 
disease (CKD) in the population. The indications for performing a renal biopsy 
vary among nephrologists, stated largely by the presenting signs and symptoms. 
This is an important issue since there is a number of settings in which a renal 
biopsy is not indicated, thus avoiding the potential risk of bleeding and other 
complications associated with renal biopsy.  
The overall rate of native kidney biopsy (in number of procedures per mil-
lion population (pmp) varies from over 250 pmp in Australia to less than  
75 pmp in the United States (Briganti et al. 2001). The renal biopsy rate is 
higher in adults than in children. These differences in the renal biopsy rate are 
not driven by the differences in the spectrum of renal pathology, but rather by 
the opinions regarding the value of the procedure in diagnosis, prognosis, and 
therapy. In many academic medical centers including ours, the biopsies of the 
transplanted kidney exceed those performed to diagnose a disease in the native 
kidney.  
In the patients with asymptomatic microscopic haematuria (AMH) (ie, 
persistent microscopic haematuria with dysmorphic red blood cells, negative 
"dipstick" for proteinuria, normal serum creatinine concentration, and normal 
blood pressure), as well as isolated non-nephrotic proteinuria (LGP) (less 
than 0,5–1 g/24 h, ie, the absence of glomerular haematuria, normal renal 
function, and the absence of clinical or serologic evidence of a systemic disease 
that can cause glomerulonephritis), the renal biopsy may not alter therapy, as 
these patients generally have a good prognosis. So, in these cases a renal biopsy 
is generally not performed. When biopsies are performed, they typically 
demonstrate either a normal kidney biopsy or one of three disorders in persis-
tent microscopic haematuria: IgAN, hereditary nephritis (Alport syndrome), or 
thin basement membrane disease; isolated non-nephrotic proteinuria may be 
present in e.g. systemic lupus erythematosus, vasculitis, or a paraproteinemia. 
Most patients with IgAN and thin basement membrane disease without protei-
nuria have a good long-term prognosis and, other than angiotensin-converting 
enzyme inhibitors, there is no clear effective therapy for any of these condi-
tions. Some of the patients with isolated non-nephrotic proteinuria will have 
mild primary focal segmental glomerulosclerosis, IgA nephropathy, or membra-
nous nephropathy (Hall et al. 2004); however, immunosuppressive therapy 
would not be indicated in this setting, since the prognosis with non-nephrotic 
proteinuria is often excellent.  
As a result, a renal biopsy is not routinely performed in many medical 
centres accross the world for isolated asymptomatic microscopic haematuria or 
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isolated non-nephrotic proteinuria to establish a specific diagnosis, at least in 
the United States, unless there is coexisting proteinuria or the evidence of renal 
insufficiency. The biopsy is indicated for coexisting AMH and LGP identifying 
major and potentially progressive nephropathies in 70% of patients who should 
be managed by nephrologists (Richards et al. 1994, Hall et al. 2004, Coppo et 
al. 2010). However, these data suggest that the knowledge of renal histology is 
essential in the management of the patients with a renal disease. This is parti-
cularly true with IgA nephropathy since the majority of patients who are first 
seen with isolated microhematuria have a progressive disease (Szeto et al 2001). 
According to Coppo and collaborators, mild cases of IgAN are surely missed as 
screening programs do not exist, with the exception of some Asian countries, 
including Japan, Korea and Taiwan (Coppo et al. 2010).  
In this light, in some European medical centres including ours and also in 
Japan, the patients with asymptomatic persistent microscopic haematuria are 
included in the kidney biopsy procedure which gives a diagnosis as well as a 
chronicity level to clinicians for the further management of the patients with 
early and mild IgAN disease or allows excluding hereditary disorders. And, this 
is also the purpose of the Oxford classification – to find out a MEST score 
which may help in the management of patients during a long-lasting disease 
course.   
 
 
6.1.2. Occurrence of Glomerulopathies in  
the Estonian Population  
Glomerulonephritis is a relatively rare disease with numerous subtypes which 
are possible to identify by renal biopsy. Our study presents the epidemiological 
data and the patterns of primary glomerulopathies diagnosed by renal biopsy 
over a 10-year period in Estonia. IgA nephropathy was the most common 
glomerular disease in our renal biopsy material (35.5%), comprising 34.7% of 
primary glomerulopathies in adult groups. The occurrence of IgAN in Estonia, 
as in most European countries, such as the Czech Republic, Italy, France, Ro-
mania, Portugal, Lithuania, Finland and Germany (Simon et al. 2004, Rychlik et 
al. 2004, Covic et al. 2006, Carvalho et al. 2006, Beitnaraite et al. 2007, Wirta 
et al. 2008, Werner et al. 2009, Braun et al. 2011), and some South American 
countries, e.g. Brazil (Polito et al. 2009) and in China as well (Li, Liu 2004) is 
the most common, with percentages of 28.9–46% typically found. Its incidence 
in the USA is around 22% (Pesce, Schena 2009). The low occurrence of IgAN 
in the USA may be explained by different indications and low frequency of 
renal biopsy. According to the 2009 IgA nephropathy study, IgAN frequency 
mostly depends on an ethnic group, and it is less frequent in some Asian 
countries; for example, in India and Saudi Arabia, and the IgA nephropathy 
percentages in South Africa were only 5.8–8.6% (Narasimhan et al. 2006, 
Jalalah 2009, Okpechi et al. 2010). It is possible that the differences of 
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occurrence in the black and white people in the USA and South Africa may be 
influenced by different indications for renal biopsy.  
An important finding in our study was the fact that the occurrence of MPGN 
in Estonia was not high (n = 19, 7.7%, mean age 50.2 ± 18.0 years). The occur-
rence of MPGN is much lower than in the earlier period (11.7%) (Ots 1998). 
Infection with hepatitis C virus and human immunodeficiency virus (HIV) are 
recognized as an important cause and consequence of CKD (Izzedine et al. 
2009), and the decreased prevalence of MPGN is probably associated with the 
better control of chronic persistent viral and bacterial infections. A low fre-
quency of MPGN has also been reported in the other developed European 
countries (Polenakovic et al. 2003, Rychlik et al. 2004,Werner et al. 2009,Braun 
et al. 2011), in contrast with Romania where the frequency of MPGN has been 
shown to be still high, 29.4% (Covic et al. 2006). 
Non-inflammatory glomerulopathies (FSGS, MCD and MGN) which usually 
manifest themselves with nephrotic syndrome, were also frequent in the biopsy 
material (34.6%). Comparing the data of 1991–1994 with those of 2001–2010, 
the increase in these glomerulopathies from 12% to 34.6% was reported (Ots 
1998). In the present study FSGS was the most frequent disease (16.1%), 
followed by MCD (14.1%) and membranous nephropathy (4.4%). In the 
children’s group, the changes towards non-inflammatory glomerulopathies were 
noticed. There were no cases of FSGS in the children’s group (≤15 years old); 
however, MCD was the main non-inflammatory primary glomerulopathy in this 
group. Comparing the data of 1991–1994 with those of 2001–2010, the fre-
quency of MCD in the children’s group increased by 53.8% (n = 7 cases, 
previously n = 0 cases). This trend is probably related to the changes in the indi-
cation for renal biopsy, along with more active work by paediatric nephrologists 
in the intensive diagnostics of idiopathic nephrotic syndrome. The occurrence of 
MCD in adult groups was higher than in the children’s group (n = 27, 11%). 
FSGS was the most frequent disease in the older adult group (n = 20, 8.0%), 
and 9 cases of FSGS were diagnosed in the elderly group. 11 cases of MGN 
were registered (five males and six females). The occurrence of non-inflam-
matory glomerulopathies in Estonia (34.6%) is comparable with the other 
studies performed in Western Germany (43%, Werner et al. 2009), Northern 
Germany (40%, Braun et al. 2011), Finland (20.5%, Wirta et al. 2008), the 
Czech Republic (31.2%, Rychlik et al. 2004), Lithuania (31.9%, Beitnaraite et 
al. 2007), Macedonia (30.6%, Polenakovic et al. 2003), Russia (26.8%, Dzha-
naliev et al. 2002), Romania (31.2%, Covic et al. 2006), Iran (55.3%, Moham-
madhoseiniakbari et al. 2009), Saudi Arabia (49–52.4%, Jalalah 2009) and India 
(38.4%, Narasimhan et al. 2006). The increase in the occurrence of primary 
FSGS, as observed in non-European countries such as Jamaica, Saudi Arabia, 
India and Brazil (Narasimhan et al. 2006, Jalalah 2009, Polito et al. 2009, 
Soyibo et al. 2009), could not be demonstrated in the Western and Central 
European countries and neither in Estonia. 
The frequency of secondary glomerulopathies in Estonia (n = 122, 22.3%) 
was lower than in the other European countries (25.4–29.4%) and some South 
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American countries (55.5%), but similar or lower than in Asian (17.2%) and 
some non-European countries (Rychlik et al. 2004, Beitnaraite et al. 2007, 
Braun et al. 2011). Official databases clearly show that a policy in the renal 
biopsy practice plays an important role (Pesce, Schena 2009). The annual 
kidney biopsy rate per 105 of the population in Estonia (8.1) is comparable with 
the other European countries, exept Finland (17.6) (Wirta et al. 2008), reflecting 
a good biopsy indication policy. The annual incidence of biopsy-proven glome-
rulonephritis (any, primary or secondary) was 4.5 which is medium compared 
with the data of the other European centres (3.4–9.3) (Wirta et al. 2008). The 
Estonian population is very small (1.34 million) and therefore some rare 
diseases of glomeruli, such as cast nephropathy or paraproteinic deposition 
disease, and some hereditary diseases were found only in limited numbers. A 
kidney biopsy was not generally performed in patients with diabetes mellitus. 
Our study contains the largest continuous single-centre renal biopsy material 
data in Estonia and reflects the demographic picture of the occurrence of 
glomerular diseases in the country.  
 
  
6.2. IgAN Study in the Estonian Cohort  
6.2.1. Patients 
The study presents the long-term follow-up data of IgAN patients with the kid-
ney biopsy diagnosis performed at the Tartu University Hospital. We applied 
the Oxford classification of IgAN to re-classify all cases. The main demo-
graphic, clinical and pathology data as well as the treatment of 64 Estonian 
IgAN patients were evaluated. The patients were followed for an average of 4.1 
years similarly to some other IgAN studies (Cattran et al. 2009, Maixnerova et 
al. 2011, Le et al. 2011, Alamartine et al. 2011, Tanaka et al. 2013), repre-
senting the whole spectrum of the cases appearing in the local clinical practice.  
Probably, the most interesting characteristics of the cohort were that more 
than half of the patients had only persistant microscopic haematuria presenting 
very early or a mild disease. 
According to Coppo and collaborators, mild cases of IgAN are surely missed 
in many medical centres as screening programs do not exist (Coppo et al. 
2010). Our IgAN patients’ cohort contained main part (55%) of the patients 
having normal initial eGFR and only 11% of the patients having eGFR 
<60 ml/min/1.73 m² at the time of biopsy unlike other similar studies where 
clinicomorphological correlations, using the Oxford classification, have recently 
been investigated (Barbour et al. 2016). The mean eGFR of the patients of the 
Oxford original study (Cattran et al. 2009), North American validation study 
(Herzenberg et al. 2011) and VALIGA study (Coppo et al. 2014) was 68.4 
ml/min/1.73 m² but in our cohort the mean eGFR was 94.9 ml/min/1.73 m² 
which means that the main part of our patients were biopsied in a clinically 
asymptomatic stage of the disease. However, this difference may give some 
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advantages like a duly identification and the subsequent mild disease, allowing 
to assess the impact of clinical and morphological risk factors on the renal 
function decline in the untreated IgAN patients and the patients with different 
treatment regimes. 
  
 
6.2.2. Clinical and Morphological Data Correlations and  
Gender-related Differences in IgAN Patients  
Our main findings were: first, as in the Oxford classification study (Roberts et 
al. 2009, Cattran et al. 2009), the Estonian cohort’s pattern of mesangial hyper-
cellularity, endocapillary hypercellularity, segmental sclerosis/adhesion and 
tubular atrophy/interstitial fibrosis (MEST) confirmed having a correlation with 
the clinical data as their higher score was linked to the eGFR decline; second, 
we found a statistically significant correlation between the M1 and the eGFR 
decline in males, but not in females. This finding shows that gender-related 
differences have a prognostic value of M1 in males. 
Although gender-related differences have someway been observed or even 
reported in other papers (Cattran et al. 2009, Maixnerova et al. 2011, Le et al. 
2011, Tanaka et al. 2013, Zeng et al. 2012), this investigation, in our opinion, is 
the first study directly addressing these differences and finding such an con-
siderable result.  
According to our study, higher mesangial score (M1) did not correlate with 
the eGFR decline in female patients, furthermore, it did not have an impact on 
an unfavourable IgAN outcome, showing little eGFR changes during the 
follow-up and highlighting the difference of the disease progression in males 
and females.     
In the pathology baseline data we noticed a relatively better starting position 
in the male patients’ group compared to females. According to the Oxford 
classification, M0E0S0T0 in male and female groups was 21% and 15%, re-
spectively. However, among higher scores, female patients had more cases of 
higher mesangial scores (M1E0S0T0, 27% and 16% in female and male groups, 
respectively) and more cases of complex higher scores (M1E1S1T0 was 31% 
and 26%, respectively). Segmental sclerosis/adhesion cases in both groups were 
registered to a similar extent; however, the complex score M1S1 in males 
occurred more frequently (M1E0S1T0 score was observed in 37% males and 
27% females) as well as the cases with T1 (13% and 4% in males and females, 
respectively). On the other hand, the baseline clinical data in males showed a 
correlation to the M1, whereas in females the M1 did not show any correlations 
with the eGFR (eGFR in females at M0 was 83.5±15.0 ml/min per 1.73 m² and 
at M1 was 86.6±28.1 ml/min per 1.73 m²). On the contrary, M1 was correlated 
with the eGFR in the whole cohort and in males. The other – S1 – was 
correlated with the proteinuria level and eGFR at the time of renal biopsy in 
both genders, T1 lesions with eGFR and proteinuria in males, E1 in females did 
not show correlation with eGFR, but showed correlation with proteinuria.  
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Some chronic glomerulonephritis studies have reported that females have a 
more favourable outcome in chronic glomerular disease, including IgAN, 
compared with males (Neugarten et al. 2000, Eriksen, Ingebretsen 2006) but 
other investigators have found either no gender-related differences or have 
observed women to be at a greater risk of a progressive loss of renal function 
(D'Amico 1992, Jafar et al. 2003). According to Cattran and collaborators, the 
IgAN outcome for female patients was reported as contrary results pointing to a 
worse disease outcome (Cattran et al. 2008). Cattran and collaborators, in their 
chronic glomerulonephritis study, found that a better outcome of IgAN disease 
is mostly mediated through both, lower proteinuria and blood pressure at 
presentation and throughout the follow-up, although the study reported that 
females did have an independent advantage at higher levels of proteinuria 
(Cattran et al. 2008). Our study confirms that proteinuria above 1.0 g/24hrs, 
which was associated with the E1 and S1 pathology scores, has a direct impact 
on the disease progression and on an unfavourable disease outcome in females. 
However, for the patients with proteinuria levels lower than 1.0 g/24hrs, the 
disease progression was faster in males. It is possible that the M1 score 
correlation with the eGFR decline plays an important role here, greatly affecting 
the progression of the disease in males. 
Similarly to the others (Cattran et al. 2009, Maixnerova et al. 2011, Le et al. 
2011, Tanaka et al. 2013), our results confirm the higher MEST parts (in the 
whole cohort and in the male group) being correlated with the disease 
progression. However, this was not a rule for female patients, where the M1 did 
not show any correlation with the eGFR decline. There is previously-published 
evidence available proving that the male gender is associated with a more rapid 
rate of progression of non-diabetic chronic kidney disease (Neugarten et al. 
2000, Eriksen, Ingebretsen 2006, Silbiger, Neugarten 2008), either indepen-
dently or through the modulation of other known risk factors. Our study 
confirms this in IgAN patients where we found a more rapid disease progres-
sion in males than in females although the renal biopsy revealed a milder 
pathomorphological picture.  
This study also provides a novel insight into the importance of arterio-
sclerosis as well as microhematuria. Namely, we observed arteriosclerosis being 
correlated only with microhematuria in untreated patients. Whereas this 
morphological lesion had no significant correlation in the drug-treated study 
group and microhematuria has generally been considered as a benign clinical 
symptom, we speculate that, in the long term, microhematuria may have much 
bigger importance than expected because the decline of renal function was still 
found in the untreated study group patients. Recent findings suggest a patho-
genic role for glomerular haematuria in kidney disease (Yuste et al. 2015). 
Although the majority of studies rule out a repercussion of haematuria on the 
renal outcome of patients with the IgAN, the true role of haematuria on a renal 
outcome remains uncertain (Moreno et al. 2016).   
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6.2.3. Clinical and Morphological Prognostic Risk Factors of  
Long-term Significance in the IgAN Progression  
To summarise, our study confirmed that the most significant IgAN prognostic 
morphological risk factors are segmental glomerulosclerosis and tubular 
atrophy/interstitial fibrosis and the clinical ones – proteinuria and hypertension. 
In addition, in IgAN, overweight/obesity, present at diagnosis, is associated 
with an increase in the major risk factors (hypertension, proteinuria and severe 
renal lesions) which translate into a worse final outcome (Berthoux et al. 2013). 
 
 
6.2.4. Long-term Outcome in IgAN Patients with  
Different Drug Treatment Regimes 
In our study, drug treatment was prescribed to the patients who had lower 
eGFR, higher proteinuria and more severe histological lesions. The decline of 
eGFR was noticed in all study subgroups and changing CKD group into higher 
grade was noticed among 17% of the patients. As mentioned above, the mean 
eGFR was normal in the whole IgAN cohort and, although it declined at the end 
of the follow-up, it still stayed at a near-normal level (85.8 ml/min/1.73 m²). 
The IgAN patients with less clinical symptoms (lower MAP, without protei-
nuria, with normal kidney function) stayed without treatment but the patients 
with severe clinical symptoms (higher MAP, microhematuria with proteinuria), 
lower kidney function and serious morphological lesions (S1/T1, 2) were 
treated. A similar management of IgAN where the drug-treatment is mostly 
indicated for more serious cases has also been described in many other studies 
(Barbour et al. 2016). The optimal approach to the treatment of IgAN is still 
uncertain but renoprotection is a well-known approach in the management of 
various chronic kidney diseases today following basic experimental (Anderson 
et al. 1985, Kato et al. 1999) and clinical landmark studies (Lewis et al. 1993, 
Brenner et al. 2001, Jafar et al. 2001). Our study revealed that RASb were 
generally effective in arresting the IgAN progression and diminishing protei-
nuria but RASb were not effective in patients with clinical and morphological 
risk factors present. When we assessed the study subgroups separately only 
according to clinical risk factors, the decline of eGFR was the lowest in the 
RASb treated patients with clinical risk factors. Thus, maximal renoprotection 
can be achieved when patients’ blood pressure is normal, they do not smoke and 
keep their body weight within normal range. We were able to demonstrate that 
RASb were only effective in preventing the progression when clinical risk 
factors were modest or missing. The same question was raised by other authors 
but they have failed to find similar differences in the subgroups based on 
treatment exposures (Barbour et al. 2016).  
Another aspect deserves to be pointed out. Similarly to RASb usage, CSs 
were also prescribed to the IgAN patients who had proteinuria, more serious 
morphological lesions and lower kidney function. In our cohort, the lowest 
51 
kidney function was noticed in the patients receiving CCBs or CSs. Inte-
restingly, since the KDIGO guideline now recommends CSs to the patients with 
eGFR >50 ml/min/1.73 m², we have historically used these drugs in many 
patients below a recommended level. Similar findings have also been reported 
by Coppo et al. in VALIGA study where immunosuppression was more fre-
quently used in the patients with lower eGFR (Coppo et al. 2014). These 
findings demonstrate nephrologists’ aggressive therapeutic attitude in treating 
IgAN patients with more severe CKD and, on the other hand, leaving the 
patients without severe clinical symptoms untreated.  
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7. CONCLUSIONS  
1. According to the study, we can conclude that during the period of 2001–
2010, inflammatory glomerulopathies dominated in the spectrum of primary 
glomerulopathies in the Estonian population. Comparing this data with the 
data of the period of 1991–1994, the change towards non-inflammatory glo-
merulopathies was noticed. The distribution pattern of various glomerulo-
pathies largely corresponds to the distribution described in the other Euro-
pean centres. IgA nephropathy has been the most common primary glomeru-
lonephritis in our population and it has not changed over the time (Paper I).  
2.  Asymptomatic microhematuria and asymptomatic microhematuria with 
proteinuria were the main presenting clinical syndromes in IgAN patients, 
comprising 48% and 39% of all cases, respectively. Nephrotic syndrome and 
macroscopic haematuria, which were associated with acute respiratory 
infection, were rare at presentation (7% and 4%, respectively). The typical 
finding in glomeruli was the expanding of mesangial area and the mesangial 
cell proliferation (73% of cases). Segmental glomerulosclerosis/adhesion 
and tubular atrophy/interstitial fibrosis were found in 52% and 10% of 
kidney biopsies, respectively. (Paper II).  
3. Mesangial hypercellularity, endocapillary hypercellularity, segmental 
sclerosis/adhesion and tubular atrophy/interstitial fibrosis (the MEST parts) 
have a correlation with the clinical data as their higher score was linked to 
the eGFR. We found a statistically significant correlation between the M1 
and the eGFR in males, but not in females. This finding shows that gender-
related differences have a prognostic value of M1 in males. The other – S1 – 
was correlated with the proteinuria level and eGFR at the time of renal 
biopsy in both genders, T1 lesions with eGFR and proteinuria in males, E1 
in females did not show correlation with eGFR, but showed correlation with 
proteinuria. (Paper II). 
4.  The biggest eGFR decrease after the follow-up was found among the 
patients who had clinical and morphological risk factors (hypertension, 
proteinuria, overweight/obesity, and segmental glomerulosclerosis and tubu-
lar atrophy/interstitial fibrosis). Clinical risk factors had important influence 
on long-term outcome. More rapid IgAN progression occurred in males 
compared with females through faster eGFR decline that makes prognosis 
worse (Papers II–III).  
5. Progression of IgA nephropathy was not found in the patients groups without 
risk factors and without treatment, and without risk factors and with RASb 
treatment. (Paper III). 
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9. SUMMARY IN ESTONIAN 
IgA nefropaatia uuring Oxford’i klassifikatsiooni järgi:  
IgA nefropaatia kliinilis-morfoloogilised korrelatsioonid, haiguse 
progresseerumise ja renoprotektiivse ravi efekti uuringud 
 
Sissejuhatus 
Enamik glomerulonefriite, isegi kõige sagedasemad, on harva esinevad haigu-
sed. Sellele vaatamata on nad kliinilises praktikas olulised, kuna patsiendid ei 
parane ja areneb progresseeruv krooniline neeruhaigus (KNH). (Floege et al. 
2016). Immuunoglobuliin A nefropaatia (IgAN) on kõige sagedasem glomeru-
lonefriit maailmas (Berger, Hinglais 1968, D’Amico 1987, Levy, Berger 1988, 
Glassock 2008). Kroonilise glomerulonefriidi haigeid on Eestis ligikaudu 30% 
lõpp-staadiumi neerupuudulikkuse haigete seas ja IgAN on olnud nende hulgas 
kõige sagedasem sarnaselt teistes maades läbiviidud uuringutele. Diabeetilise 
nefropaatia ja neerukahjustusega kõrgvererõhktõve kõrval on IgAN jäänud 
järgmiseks oluliseks tervishoiuprobleemiks nefroloogia valdkonnas, sest haiges-
tuvad peamiselt just noored inimesed ja haigus areneb pidevalt aeglaselt edasi. 
Kliiniliselt progresseerub IgAN erineva kiirusega ja lõpp-staadiumi neeruhaigus 
tekib ligikaudu 15% patsientidest 10 aasta jooksul (D’Amico 2000), 30% kuni 
40% patsientidest 20–30 aasta jooksul esimeste kliiniliste nähtude avaldumise 
järgselt (Lai KNe tal. 2016) ning umbes 50% patsientidest 25 aasta jooksul 
esmasest diagnoosist (Glassock 2008). IgA nefropaatia korral on neerud 
kahjustuse sihtmärgiks, kuigi esmane defekt pärineb süsteemsest aberrantsest 
O-seotud glükaanide glükosüleerimisest IgA1 ühenduspiirkonnas, mis põhjus-
tab suurenenud galaktoosi-defitsiitset IgA1 (Gd-IgA1) taset vereseerumis. 
Immuunokeemilist hälvet ei ole võimalik neerutransplantatsiooniga korrigee-
rida, mis tähendab seda, et IgAN taasteke neerutransplantaadis on sage. Efek-
tiivne ja spetsiifiline IgAN ravi tänapäevani puudub (Hsin-Hu YU et al. 2011, 
Lai et al. 2016). 
Enamike KNH, sealhulgas IgA nefropaatia korral alaneb neerufunktsioon 
kuude või aastate jooksul, mis põhjustab progresseeruva neerukahjustuse ja 
enamikel juhtudel lõpp-staadiumi neerupuudulikkuse. KNH peamisteks põhjus-
teks on mitmesugused glomerulopaatiad, eelkõige glomerulonefriidid, suhkur- 
ja kõrgvererõhktõbi. Enamikel juhtudel kulgeb neerufunktsiooni süvenemine 
varjatult, väheste kliiniliste nähtudega. Peamiste KNH progresseerumise riski-
tegurite hulka kuuluvad hüpertensioon, proteinuuria, ülekaalulisus ning morfo-
loogiliselt avastatud kroonilisuse näitajad nagu segmentaarne glomerulo-
skleroos ja interstiitsiumi fibroos/tuubulite atroofia. Erinevates maades on küm-
nete tuhandete inimeste sõeluuringute käigus uriini ja neerufunktsiooni näitajate 
põhjal avastatud, et ligikaudu igal kümnendal inimesel esineb neerukahjustus: 
mõnel inimesel kergem, mõnel tõsisem neerukahjustus, mis lõpptulemusena 
võib vajada neerude tööd asendavat ravi – dialüüsi või neeru siirdamist. Need 
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ravimeetodid aga kuuluvad ühiskonnas kulukaimate ravimeetodite hulka, mida 
saavad endale lubada vaid arenenud riigid. Seetõttu pööratakse suurt tähelepanu 
KNH varajasele avastamisele ja progresseerumise riskitegurite kõrvaldamisele. 
Kahjuks kuulub ka IgAN nende KNH hulka, mille kulg on varjatud, sest alg-
staadiumides esineb enamikel juhtudel kliiniliselt vaid mikrohematuuria. 
Päsmakestes esinev immuunpõletik areneb aeglaselt põhjustades aastate või 
aastakümnete jooksul ulatusliku neerukahjustuse, mis avaldub kliiniliselt neeru-
puudulikkuse sümptoomidena ja ureemia nähtudega. IgA nefropaatia varajaseks 
avastamiseks peavad pere- ja üldarstid olema väga tähelepanelikud uriini ana-
lüüsi interpreteerimisel ning hematuuria esinemisel kahtlustama IgAN esine-
mise võimalust. Kahjuks jõuavad nii meil kui mujal maailmas IgAN haiged 
nefroloogi juurde sageli hilinenult väljendunud kliiniliste ja morfoloogiliste 
neeruhaiguse progresseerumise riskitegurite esinemisega.      
Nimetatud asjaolud on olnud aluseks rahvusvahelise IgAN töögrupi projek-
tile ja hiljuti avaldati uus IgAN klassifikatsioon, mis põhines kliinilis-morfo-
loogilistele uuringutele (nn. Oxfordi klassifikatsioon). Selle klassifikatsiooni 
valideerimise projektis (VALIGA) osales ka käesoleva uurimistöö autor. 
Teaduskirjanduse andmetel on viimastel aastatel nüüd ilmunud mitmeid IgAN 
uurimusi, kus on kasutatud uut Oxfordi klassifikatsiooni. Kuid samas, arvesta-
des IgAN leviku ulatust, võimalikke regionaalseid iseärasusi, neerubiopsia 
kättesaadavust erinevates keskustes, KNH progresseerumise riskitegurite 
varieeruvust, on veel uue klassifikatsiooni kasutuse ja kliinilis-morfoloogiliste 
korrelatsioonide kohta läbi viidud vähe uuringuid.  
Käesoleva uurimustöö üldine eesmärk oli analüüsida ühe keskuse-põhist 
neerubiopsia materjali, leida IgA nefropaatia esinemissagedus ja võrrelda eri-
nevat ravi saanud haigete kliinis-morfoloogilisi seoseid. Käesolevas disser-
tatsioonis hüpotiseerisime: 1) et IgA nefropaatia esinemissagedus ei ole oluliselt 
muutunud võrreldes varasemate sama keskuse uuringute tulemustega; 2) IgA 
nefropaatia progresseerumine on erinev meestel ja naistel; 3) renoprotektsioon 
omab IgA nefropaatia haigetel head efekti.  
 
Uuringu eesmärgid 
1. Leida erinevate glomerulopaatiate jaotuvus sealhulgas IgAN osakaal 
glomerulopaatiate seas neerubiopsia materjali põhjal Tartu Ülikooli 
Kliinikumis. 
2. Analüüsida IgAN kliinilist leidu ja haiguse morfoloogiat biopteerimise 
ajal vastavalt Oxfordi klassifikatsioonile.  
3. Hinnata kliiniliste ja morfoloogiliste andmete korrelatsioone IgAN 
patsientidel ja võrrelda nende soolisi erinevusi.  
4. Hinnata kliinilisi ja morfoloogilisi riskitegureid ja nende pikaajalist 
mõju IgAN progresseerumisele. 
5. Analüüsida renoprotektsiooni mõju IgAN patsientidel jälgimisperioodi 
järgselt.  
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Uuritavad ja uurimismeetodid 
Kliinilis-morfoloogilised retrospektiivsed uuringud viidi läbi Tartu Ülikooli 
Kliinikumis (TÜK). Uuriti 2001–2010 kõikide neerubiopsiate materjal, kokku 
578 juhtu. 31 juhtu arvati välja ebapiisava biopsia materjali tõttu. Kokku oli 547 
patsientide neerubiopsia andmed lisatud uuringuse I (340 mest, 238 naist; 
keskmine vanus 39.9 ± 17.9 aastat). Viis protsenti patsientidest olid lapsed. 
Täpsed rahvaarvu andmed saadi Eesti Statistika andmebaasist neerubiopsia 
sageduse ja glomerulopaatiate esmaste juhtude levimuse arvutamiseks. 2010 
aastal saabus neerubiopsia materjal TÜK Patoloogiateenistusse kõikidest Eesti 
haiglatest, mis võimaldas arvutad neerubiopsia sageduse, milleks oli 8.1 per 105 
rahvastikust. (Artikkel I). Kümne aasta jooksul registreeriti 88 IgA nefropaatia 
juhtu (Artiklid II, III). Uuringust II–III arvati välja 15 patsienti, sest nende 
neerubiopsia materjal sisaldas vähem kui 8 päsmakest ja 73 IgAN patsiendist 
kohort oli moodustatud. Teiste maade uuringute andmetega võrdlemiseks 
määrasime patsientide vanusegrupid järgmiselt: lapsed ≤15, noored täiskasva-
nud 16–40, vanemad täiskasvanud 41–65 ja eakad >65 aasta vanused inimesed 
kõikides uuringutes.  
Järeluuringu kohorti modustas 64 IgAN patsienti (59% mehed, 41% naised). 
Üheksa patsiendi andmeid ei saanud järeluuringus kasutada: 3 patsienti surid 
trauma või teiste haiguste tõttu, 1 patsiendil oli terminaalne neerupuudulikkus 
haiguse diagnoosimise ajal, 5 patsientdl ei olnud teostatud vajalikke uuringuid.  
Uuringul on Tartu Ülikooli inimuuringute eetikakomitee luba.  
Kliinilised ja laboratoorsed andmed koguti haiguslugude põhjal neeru-
biopsia teostamise ajal ja jälgimisperioodi lõpus. Uuringusse kaasati patsiendid 
kõikidest vanuse rühmadest. Koguti järgmisi kliinilisi andmeid: kliiniline sünd-
room, vererõhk, kehakaal, pikkus, suitsetamine, laboratoorsed analüüsid (kreati-
niin, kolesterool, albumiin, valk uriinis), kasutatud ravimid. Seerumi kreatiniini 
taseme alusel arvutati glomerulaarfiltratsiooni kiirus (arvutuslik ehk estimated, 
eGFR) ning kehakaalu ja pikkuse alusel arvutati kehamassiindeks (KMI), kus 
KMI üle 25/30 peeti ülekaalulisteks/rasvunuteks . KNH jaotati vastavalt kaas-
aegsele ravijuhendile viide raskuskategooriasse (G1-G5) (KDIGO 2013). Klii-
nilised sündroomid IgAN esmase diagnoosi korral olid järgmised: asümpto-
maatiline mikrohematuuria, makrohematuuria, asümptomaatiline mikrohema-
tuuria koos proteinuuriaga, nefrootiline sündroom, äge neerupuudulikkus, kroo-
niline neerupuudulikkus.  
Patomorfoloogilised andmed on kõik hinnatud ja klassifitseeritud käesole-
va uurimistöö autori poolt. Iga bioptaat uuriti valgusmikroskoopiliselt ja im-
muunfluorestsents (IF) meetodi abil. Kogu uuritud neerubiopsia materjali põhjal 
klassifitseeriti neeruhaigused, süvendatult uuriti IgAN morfoloogiat lisaks teise, 
sõltumatu patoloogi poolt. 
Käesolevas töös on kasutatud uue Oxfordi klassifikatsiooni töölehte, kus 
hinnati morfoloogilisi parameetreid järgnevalt: mesangiaalne hüpertsellulaarsus 
(M), endokapillaarne proliferatsioon (E), segmentaarne glomeruloskleroos (S) 
ja interstiitsiumi fibroos/tuubulite atroofia (T) – nn. MEST skoor. Iga IgAN 
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neerubiopsia juhu analüüsimisel hinnati erinevaid neerukoe piirkondi järgne-
valt: totaalne päsmakeste arv, mesangiaalne hüpertsellulaarsus, M0/M1 (< või 
ekvivalentne 50%/ >50% päsmakestes rohkem kui 4 mesangiumi rakku ühes 
piirkonnas); endokapillaarne proliferatsioon, E0/E1 (esinemine/puudumine), 
segmentaarne glomeruloskleroos/adhesioon, S0/S1 (esinemine/puudumine); 
päsmakeste perifeersete kapillaarilingude membraanide duplikatsioon, nekroos, 
tsellulaarsed/fibrotsellulaarsed poolkuud (esinemine/puudumine). Interstitsiaal-
set fibroosi ja tuubulite atroofiat käsitleti ühe tunnusena. Vastavalt Oxfordi 
klassifikatsioonile, hinnati tuubulite atroofiat või interstitsiaalset fibroosi neeru-
koore osas, mis oli protsentuaalselt suurem. Tubulaarne atroofia/interstitisaalne 
fibroos, 0–25% (T0), 26–50% (T1), >50% (T2). Lisaks kategoriseeriti vere-
soonte muutused järgnevalt: arterioskleroos: puudumine (A0), mõõdukas (A1) 
(intima fibroos < kui veresoone seina lihaskest) või raskekujuline (A2) (intima 
fibroos > kui veresoone seina lihaskest); arteriolohüalinoos (esinemine/puu-
dumine). IF leidu hinnati vastavalt Oxfordi klassifikatsiooni juhistele. 
Statistiline analüüs. Kõik andmed oli kogutud ja salvestatud andmebaasis 
Excel. Kogutud andmete analüüsimiseks kasutati statistikaprogrammi Statistica 
12.0, mille alusel on tehtud kirjeldav statistika kogutud morfoloogiliste ja 
kliiniliste andmete kohta (keskväärtused, standardhälbed) soo- ja vanusgruppide 
kaupa kohordis. Kvalitatiivsed andmed olid esitatud kui absoluutsed ja relatiiv-
sed sagedused. Kvantitatiivsed andmed olid väljendatud kui standardhälvete 
intervallid, lubatud statistilise vea piiriks oli 5% (p ≤0.05). 
Erinevate uuritavate gruppide tunnuste keskväärtuste hindamisel ja vara-
semate andmetega võrdlemiseks kasutati Student’s t-testi. Ühe aasta neeru-
biopsia esinemissagedus oli defineeritud kui neerubiopsiate arv aastas 105 
rahvastikust. 
Spearmani korrelatsiooni kasutati kahepoolsete seoste hindamiseks. Neeru-
funktsiooni vähenemise määr oli väljendatud kui eGFR kõver jälgimisperioodi 
lõpus, mida hinnati kui kliinilist tulemust. Mediaanid võrreldi kasutades Mann–
Whitney U testi. Pidevad muutujad võrreldi kasutades Student t-testi sõltuma-
tute valimite jaoks pärast normaaljaotuse kontrollimist. Kolmogorov-Smirnovi 
testi või dispersioonanalüüsi (ANOVA) kasutati, kui oli tarvis rohkemaid 
patsientide rühmi võrrelda. Hinnati eGFR languse erinevusi uuritud rühmade 
vahel kasutades Wilcoxoni summa testi pidevmuutujate erinevuste hindamiseks. 
Ühe- ja mitme muutujaga logistilist regressiooni kasutati uurimaks seoseid 
sõltumatu ja sõltuvate muutujate vahel. Sõltumatud muutujad olid: vanus, sugu, 
KMI, MAP, eGFR, proteinuuria, vererõhk, suitsetamine. Spearman korrelat-
siooni kordajat kasutati kahepoolsete kliinilise muutujate ja morfoloogilised 
skooride vahel seoste hindamiseks.  
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Tulemused 
1. Glomerulopaatiate esinemissagedus Eestis (Artikkel I) 
 
Primaarsed glomerulopaatiad (248 juhtu) moodustasid peamise rühma (45,4%) 
kõikidest informatiivsetest neerubiopsiatest (547) ja IgAN moodustas nendest 
põhiosa (88 juhtu, 35,5%). Glomerulaar- ja tubulointerstitsiaalsete haiguste jao-
tus neerubiopsia materjali põhjal on esitatud artiklis I, Tabel 1. Primaarsete 
glomerulopaatiate seas põletikulised glomerulopaatiad domineerusid (63.4%). 
Mesangioproliferatiivne GN oli kõige sagedasem päsmakeste kahjustus (41.2%) 
ja IgAN moodustas kõige suurema osa sellest (n = 88, 35.5%), millele järgnes 
difuusne endokapillaarne proliferatiivne GN (n = 28, 11.3%) ja poolkuude 
tekkega GN (n = 8, 3.2%). Membranoproliferatiivne GN oli harva esinev 
päsmakeste kahjustus Eestis (7.7%). Mittepõletikulised glomerulopaatiad (mini-
maalsete muutustega haigus (MCD), membranoproliferatiivne GN ja fokaal-
segmentaarne glomeruloskleroos (FSGS) moodustasid 34.6% kõikidest pri-
maarsete glomerulopaatiate juhtudest (50 meest, 36 naist), ja 0.9% juhtudest 
moodustas skleroseeriv GN. FSGS oli kõige sagedasem (n = 40, 16.1%, kesk-
mine vanus 49.7 ± 16.7 aastat), millele järgnes MCD (n = 35, 14.1%, keskmine 
vanus 31.4 ± 18.8 aastat) ja membranoosne GN (n = 11, 4.4%, keskmine vanus 
42.5 ± 11.8 aastat). Sekundaarsed glomerulopatiad moodustasid 22.3% (n = 
122) kõikidest informatiivsetest neerubiopsiatest.  
Soo ja vanusega seotud erinevused kohordis on esitatud originaalartiklis 
(Artikkel I, Tabelid 2 ja 3).  
 
2. IgAN uuring Eesti kohordis (Artiklid II, III)  
 
Patsiendid 
IgAN uurimuse jaoks selekteeriti 73 biopsiapõhist IgAN juhtu, mille moodus-
tasid 62% mees- ja 38% naispatsiendid. Uuringust lülitati välja 15 patsienti 
ebapiisava neerukoe hulga tõttu (vähem kui 8 päsmakest). Patsientide keskmine 
vanus esmaste kliiniliste nähtude ajal oli keskmiselt 33,7 aastat (16–76 aastat): 
meestel 32,0 ja naistel 36,4 aastat. IgAN ei esinenud laste rühmas (≤15 aastat) ja 
ainult 2 juhtu oli registreeritud eakate rühmas (0.8%). 
 
Kliinilised ja laboratoorsed andmed 
Kliinilise ja laboratoorsed andmed on esitatud artiklis II, Tabel 1. Keskmine 
ajavahemik haiguse algusest ja esimesestest kliinilistest nähtudest oli 2,6 aastat. 
Üldiselt, diagnoosimise ajal oli meestel kõrgem eGFR ja mitte keegi neist ei 
olnud saanud immuunsupressiivset ravi sekundaarsete haiguste tõttu. Kõige 
sagedasemateks kliinilisteks sündroomideks olid IgAN korral mikrohematuuria 
ja asümptomaatiline mikrohematuuria proteinuuriaga, vastavalt 48% ja 39% 
juhtudest. Nefrootiline sündroom (NS) moodustas 7%, makrohematuuria 4% ja 
patsiente ägeda või kroonilise neerupuudulikkusega (eGFR˂60 ml/min/1,73m²) 
oli kummaski rühmas üks haigusjuht. MAP neerubiopsia ajal oli 94,5± 
16,7 mmHg ja 7% patsientidest olid hüpertensiivsed ja/või vajasid antihüperten-
74 
siivset ravi. Keskmine proteinuuria neerubiopsia ajal meestel ja naistel oli 
sarnane, vastavalt 0,95 g/ööp ja 0,86 g/ööp ning 81% patsientidest esines 
vähene proteinuuria <1 g/ööp. Keskmine eGFR oli 94,9 ± 30,7 ml/min/1,73m² 
ja eraldi meestel 100,5 ± 32,7 ml/min/1,73m² ning naistel 85,8 ± 25,3 ml/min/ 
1,73m². KNH raskuskategooria määramiseks kasutati eGFR andmeid: G1, G2 ja 
G3 kategooria esines vastavalt 55%, 34% ja 10% patsientidest kliinilise leiu 
avaldumise ajal, ühel patsiendil oli G4 raskuskategooria ja G5 raskuskategooria 
haigusjuhte ei olnud. Jälgimisperioodi lõpus oli patsientide jaotuvus KNH 
raskuskategooria järgi järgmine: G1 – 52%, G2 – 29%, G3 – 16% ja G4 – 3%. 
Teiste kliiniliste andmete osas nagu KMI, suitsetamine või tonsillektoomiaei 
esinenud olulisi erinevusi meeste ja naiste vahel: KMI oli normist kõrgem mõle-
ma soo patsientidel ja ülekaalulised/rasvunud patsiendid moodustasid meeste ja 
naiste rühmades vastavalt 58% ja 65%.    
 
Patomorfoloogilised iseärasused 
Tüüpiline päsmakeste leid oli mesangiaalse maatriksi hulga suurenemine ja 
mesangiaalsete rakkude proliferatsioon (73% juhtudest). Enamikel juhtudest 
olid need muutused globaalsed ja difuussed ning varieerusid kergest raske-
kujuliseni. Segmentaarset glomeruloskleroosi/adhesiooni leiti 52% neeru biop-
taadis, endokapillaarset tsellulaarsust 32% proovides, üksikuid parietaalse 
nefroteeli poolkuid leiti mõnedes bioptaatides, tuubulite atroofiat/interstitsiaal-
set fibroosi esines 10% neeru bioptaatides ning arteriosklerootilist kahjustust 
esines 35% kõikidest juhtudest. A0-A2 ja arteriolohüalinoos ei ole Oxfordi 
klassifikatsiooni osa, kuid lülitati antud uuringusse kui oluline morfoloogiline 
tunnus, mis on seotud hüpertensiooni ja tõenäoliselt ka hematuuriaga. Viimasele 
sümptoomile ei ole varasemalt olulist tähtsust IgAN progresseerumisele pööra-
tud. Päsmakeste kahjustuse mustris ei olnud olulisi muutusi meeste ja naiste 
gruppide vahel. 
Muutused ilmnesid aga tuubulite atroofia/interstitsiaalse fibroosi ja arterio-
skleroosi kategooriates meeste prevaleerumisega rohkem kui kaks korda mõle-
mas neist, mehed-naised: vastavalt 13%–4% ja 40%–18%.  
 
Järeluuring (FU) 
Üheksa patsienti andmeid ei saanud jälgimisperioodi (follow-up, FU) lõpul 
kasutada, kuid ülejäänud 64 patsiendi jaoks oli FU 4,1 aastat. Esialgsed ja FU 
kliinilised andmed on esitatud artiklis II, Tabel 1. Lõplik esmaste ja FU and-
mete võrdlus teostati ainult nendel juhtudel, mil mõlema perioodi andmed olid 
analüüsi jaoks kättesaadavad (kokku 64 patsienti). Medikamentoosset ravi sai 
58% patsientidest. Ravi saanute rühma patsiendid olid märkimisväärselt vane-
mad (37,5 vs 28,8, p = 0,04), ülekaalulisemad (27,5 vs 25,2, p = 0,02), kõrgema 
seerumi kreatiniini tasemega (106,1 vs 77,2, p = 0,02) ja nendel oli madalam 
eGFR kui ravi mittesaanud patsientidel (vastavalt 76,5 vs 98,8, p = 0,01) 
(Artikkel II, Tabel 1). Sarnane kliiniline pilt ja ravimite määramine leiti vasta-
valt kliinilisele sündroomile moodustatud patsientide rühmades (Artikkel III, 
Tabel 2). RASb oli määratud patsientidele, kellel oli parem neeru funktsioon ja 
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madalam vererõhk. Madalam neerufunktsioon esines aga kaltsiumikanali blo-
kaatoreid (calcium channel blockers, CCB) saanud patsientidel (Artikkel III, 
Tabel 3). 
FU lõpus esinenud kliinilised sündroomid IgAN haigetel oli üldiselt sarnased 
esmasele haiguse avaldumisele (Artikkel III, Tabel 2). Juhtivateks sündroo-
mideks mitteravitute seas olid makrohematuuria (11,1%), mikrohematuuria 
(59,3%) ja asümptomaatiline mikrohematuuria proteinuuriaga (29,6%) ning 
ravitud patsientide seas makrohematuuria haigusjuhte ei registreeritud, vähem 
oli mikrohematuuria juhte (34,2%) ja rohkem proteinuuriaga mikrohematuuria 
haigusjuhte (50,0%).  
 
Korrelatsioonid patomorfoloogiliste ja kliiniliste leidude vahel 
neerubiopsia ajal  
Kõige madalam MEST skoor oli patsientidel makrohematuuriaga, kellel klii-
niline leid oli vähene ja kes ei saanud ravi. IgAN patsientidel NSga oli kõige 
kõrgem MEST skoor ja kõige drastilisem kliiniline presentatsioon. Patsiendid 
NSga said kestvat antihüpertensiivset ravi ja ajutist ravi glükokortikosteroidi-
dega. Kõrgem MEST skoor leiti ka patsientidel asümptomaatilise mikrohema-
tuuria ja proteinuuriaga, kusjuures 2/3 nendest patsientidest (71%) said kestvat 
antihüpertensiivset ravi (Artikkel III, Tabel 2). Ravi oli määratud patsientidele, 
kellel oli madalam eGFR, kõrgem proteinuuria ja raskem morfoloogiline leid. 
Minimaalse kliinilise kuluga patsientidele ei olnud ravi määratud. 
 
Korrelatsioonid kliinilise presentatsiooni ja tulemuse vahel 
Neerufunktsiooni alanemine eGFR alusel oli meestel kiirem kui naistel isegi 
lühemas FU perioodis (Artikkel II, Joonis 1). Neeru funktsioon alanes keskmi-
selt -2,6 ml/min/1,73 m² aastas, p<0,05 (-3,4 ml/min/1,73 m² meestel, p<0,05, ja 
-0,7 ml/min/1,73 m² naistel). Uuringu lõpus esines 3% juhtudest G4 raskus-
kategooria ja G5 juhte ei registreeritud (Artikkel II). 
Ravitute ja mitteravitute haigete gruppide võrdlemisel leiti arvukalt statistili-
selt olulisi korrelatsioone. Ravitud haigete uuringurühmas algselt esinenud 
paljud kliinilis-morfoloogilised olulised korrelatsioonid kadusid ja ainult  
mõned neist jäid nagu M korrelatsioon proteinuuriaga (FU), E korrelatsioon 
MEST sagedus meestel ja naistel oli sarnane, välja arvatud  arterioskleroos, mis 
oli sagedasem meespatsientidel (p=0,004). Korrelatsioone MEST osade ja 
arterioloskleroosi, samuti MAP taseme vahel kohordis ja mõlemas meeste ja 
naiste rühmas eraldi ei esinenud (Artikkel II, Tabel 2). Siiski, M1, E1, S1, T1 ja 
A2 korreleerusid eGFR ja proteinuuria tasemetega. Samade patomorfoloogiliste 
kategooriate korrelatsioonid selgitas välja mees- ja naispatsientide vahel järg-
mised erinevused: statistiliselt oluline korrelatsioon esines meeshaigete rühmas 
MEST osade ja eGFR ning arterioskleroosi ja proteinuuria vahel, E1 ei 
esinenud märkimisväärset korrelatsiooni proteinuuriaga. Naishaigete rühmas ei 
olnud usutavat korrelatsiooni MEST osade ja eGFR vahel, välja arvatud 
korrelatsioon proteinuuria ja E1 ning S1 vahel,  M1 osas korrelatsiooni eGFRga 
ei esinenud. 
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IgA progresseerumise riskitegurid 
Neerufunktsiooni langus oli leitud kõikides uuritud patsientide rühmades 
(Artikkel III, Joonis 1A). eGFR muutused esinesid alljärgmiselt: eGFR alane-
mine registreeriti 54,8% patsientidest, 12% patsientidest jäi eGFR samale 
tasemele ja 30,2% patsientidest eGFR kergelt suurenes. ANOVA uuringu järgi 
leiti eGFR langus üldiselt kõikides uuringurühmades vaatamata sellele, kas nad 
said ravi või ei ja kas nendel esinesid kliinilised või morfoloogilised riski-
faktorid. (Artikkel III, Joonis 1B). eGFR languse trend leiti nendes patsientide 
subgruppides, kus esinesid kliinilised, morfoloogilised või mõlemad riskitegu-
rid, kuid mis statistiliselt jäi mitteusutavaks. Kasutades Mann-Whitney võrdlus-
testi analüüsisime IgAN ravi saanute rühmi eraldi. Analüüsi tulemusena leid-
sime, et patsientidel oli madalam neerufunktsioon (eGFR <60 ml/min/1.73 m²), 
kõrgem MAP (p < 0,01) ja proteinuuria vaatamata sellele kas patsiendid said 
(p< 0,01) või ei saanud RASb ravi (p< 0,01). FU proteinuuria taseme erinevusi 
ei olnud. Lõpuks moodustasime täiendavalt uuritavate rühmad vastavalt ainult 
kliinilistele riskiteguritele (ülekaalulisus/tüsedus, hüpertensioon, suitsetamine ja 
proteinuuria) ja leidsime järgneva tulemuse: ravita ja kliiniliste riskiteguritega 
patsientidel oli eGFR alanemine 13% algsest ning nendel patsientidel, kellel 
esinesid kliinilised riskitegurid ja kes said RASb ravi, eGFR langus oli 10,5%, 
siiski sellel erinevusel ei olnud statistilist usutavust. (Artikkel III, Joonis 1c).  
 
Järeldused 
proteinuuriaga (FU); S korrelatsioon eGFRga (FU) ja S korrelatsioon U-Prot 
(FU), mis oli olemas ka esimesel uuringul; T korrelatsioon kreatiniiniga ja 
eGFRga (FU). Seega, M1, E1, S1, T1 ja A2 korreleerusid MAP, eGFR ja 
proteinuuriaga. Kõrgem arterioskleroosi skoor ja MEST skoor leiti nendel 
patsientidel, kellel FU lõpus oli kõrgem proteinuuria ja madalam eGFR. Ravi-
mata patsientide rühmas esines ainult üks statistiliselt oluline korrelatsioon 
patomorfoloogiliste ja kliiniliste riskifaktorite vahel: korrelatsioon arteriolo-
skleroosi ja mikrohematuuria vahel (rs = -0,4, p = 0,04). 
1. Käesoleva uurimustöö raames läbi viidud neerubiopsia materjali analüüsil 
leiti, et primaarsete  glomerulopaatiate rühmas esinesid kõige sagedamini 
glomerulonefriidid ehk põletikulised glomerulopaatiad, mille hulka kuulub 
ka IgAN. Võrreldes uuringu andmeid 1991–1994 läbiviidud uuringuga tähel-
dasime muutust mittepõletikuliste glomerulopaatiate esinemise suurenemise 
suunas. Erinevate glomerulopaatiate levimus sarnaneb teiste Euroopa maade 
neerubiopsia uuringute tulemustega. IgA nefropaatia oli kõige sagedasem 
glomerulonefriit meie populatsioonis ja selle levimus ei ole muutunud aja 
jooksul. (Artikkel I). 
2. Asümptomaatiline mikrohematuuria and asümptomaatiline mikrohematuuria 
proteinuuriaga olid peamised kliinilised sündroomid IgAN haigetel moodus-
tades vastavalt 48% ja 39% kõikidest juhtudest. Nefrootiline sündroom ja 
makroskoopiline hematuuria, mis olid seotud peamiselt ägeda respiratoorse 
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infektsiooniga, esines harva biopteerimise ajal (vastavalt 7% ja 4%,). Tüüpi-
line leid päsmakestes oli mesangiaalse maatriksi rohkenemine ja mesangiaal-
sete rakkude proliferatsioon (73% juhtudest). Segmentaarne glomerulo-
skleroos/adhesioon ja tuubulite atroofia/interstitsiaalne fibroos esines vasta-
valt 52% ja 10% neerubiopsiatest. (Artikkel II). 
3. Mesangiaalne hüpertsellulaarsus, endokapillaaarne hüpertsellulaarsus, seg-
mentaarne skleroos/adhesioon ja tuubulite atroofia/interstitsiaalne fibroos 
(MEST) korreleerus kliiniliste andmetega ja MEST osade kõrgemad väärtu-
sed korreleerusid eGFR. Me leidsime statistiliselt usutava korrelatsiooni M1 
ja eGFR vahel meestel, kuid mitte naistel. Teised MEST osad – S1 – korre-
leerus proteinuuria ja eGFR neerubiopsia ajal nii naistel kui meestel, T1 
korreleerus meestel eGFR ja proteinuuriaga, E1 puhul ei leitud naistel korre-
latsioone eGFR, kuid statistiliselt usutavad korrelatsioonid olid proteinuuria-
ga (Artikkel II).  
4. Suurem eGFR langus jälgimisperioodi lõpus olid patsientidel, kellel esinesid 
nii kliinilised kui morfoloogilised riskitegurid (hüpertensioon, proteinuuria, 
ülekaal/rasvumus, segmentaarne glomeruloskleroos, tuubulite atroofia/ 
interstitsiaalne fibroos). Kliinilistel riskiteguritel oli oluline mõju kaugtule-
mustele. Kiirem IgA nefropaatia progresseerumine täheldati meestel, kellel 
esines suurem eGFR taseme langus. (Artikkel III). 
5. IgA nefropaatia progresseerumist ei olnud patsientidel ilma riskifaktoriteta ja 
ravita ning ilma riskifaktoriteta ja RASb raviga rühmades (Paper III). 
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